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During the course of their disease, leprosy patients may experience two types of 
inflammatory reactions- erythema nodosum leprosum (ENL) or reversal reaction (RR). 
Thalidomide is effective treatment for ENL, but not for RR. Using concentrations of thalidomide 
similar to that achieved in the treatment of ENL, we investigated thalidomide’s effect on 
reactions, viability of M. leprae, and integrity of plasma membranes.   
Cells from patients with and without RR were stimulated with M. leprae (AFB), a cytosol 
fraction of M. leprae (MLSA) or DHAR (DHAR) antigen, and the effect of thalidomide on 
lymphocyte proliferation, expression of TNF-α mRNA and synthesis of TNF-α was 
investigated. Thalidomide enhanced MLSA and DHAR induced proliferation of cells from 
patients with RR.   The expression of TNF-α mRNA was variable, but thalidomide generally 
suppressed the synthesis of TNF-α. In a sub-set of RR patients, thalidomide enhanced AFB-
induced cell proliferation, and the expression of TNF-α mRNA and TNF-α.  
ENL has been described as a consequence of M. leprae antigens released from 
macrophages binding antibody and inducing inflammation. Thalidomide did not affect the 
viability of M. leprae residing in IFN-γ/LPS activated mouse macrophages, nor did it suppress 
TNF-α or nitrite.  
Drugs may be anti-inflammatory by stabilizing cell membranes. Thalidomide failed to 
protect the plasma membrane of neutrophils and THP-1 cells from osmotic lysis.   Thalidomide 
stabilized the membrane of erythrocytes from plasma free blood, but not from whole blood.  In 
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vivo, the stability of erythrocytes membranes from subjects after ingestion of thalidomide was 
not affected.  
In conclusion, thalidomide did not alter the viability of M.  leprae, nor the integrity of the 
plasma membrane of inflammatory cells.  It could enhance or suppress M. leprae antigen-
induced synthesis of TNF-α.  Interestingly, in 15 of 75 RR patients cells stimulated with AFB, 
thalidomide acted as a co-stimulant enhancing cell proliferation, synthesis of mRNA for TNF-α 
and TNF-α. Thalidomide’s enhancing effect on TNF-α in RR appears to be dependent on the 
stimulant and IL-2 signaling. As the inflammation in RR is associated with the emergence of 
antigen-reactive T-cells and TNF-α, we speculate that the use of thalidomide in the treatment of 
RR may exacerbate the reaction. 
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CHAPTER 1 INTRODUCTION 
 
1.1 History of Thalidomide 
Chemie Grünenthal, a German pharmaceutical company, synthesized thalidomide in 
1954.  It was initially produced as a potential anti-histaminic drug but later discovered to possess 
marked sedative properties. Thalidomide’s lack of toxicity in rodents at doses as high as 10g/kg 
facilitated its availability as an over-the-counter drug and by 1960, thalidomide was widely 
marketed in more than 20 countries. It quickly became a drug for the treatment of nausea 
associated with morning sickness during pregnancy. In 1961, suspicion regarding thalidomide’s 
link with birth defects characterized by severe malformations started to appear. After more than 
10,000 documented devastating cases of birth defects, thalidomide was withdrawn from the 
market in 1961 (Zwingerberger, K. and Wnendt, S., 1996). 
In 1965, thalidomide made a major comeback after the accidental discovery of its dramatic 
effect in the treatment of an immunological reaction in leprosy known as erythema nodosum 
leprosum (ENL) (reviewed in Sheskin, J., 1980). Until 1998, thalidomide in the United States 
(US) was available only as an investigative new drug from the National Hansen Disease Program 
in Carville, Louisiana. In July 1998, the Food and Drug Administration (FDA) approved 
thalidomide for the treatment of ENL (FDA, 1998). Thalidomide is currently marketed in the US 
under the name Thalomid® (Thalidomide) by Celgene Company (Warren, New Jersey). In 
March 1999, the FDA in collaboration with Celgene implemented a distribution and training 
program known as System for Thalidomide Education and Prescribing Safety (S.T.E.P.S). In 
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order to guard against fetal exposure to thalidomide, this program requires physicians and 
pharmacists to register with the FDA before they can dispense thalidomide and all patients to 
complete an informed consent process and must agree to participate in a mandatory confidential 
surveillance registry (Zeldis, J.B. et al, 1999). In November 2001, Celgene expanded the 
availability of thalidomide worldwide by signing an agreement with Pharmion (Boulder, 
Colorado) a pharmaceutical company with European and Asian branches. In 2003, Thalomid® 
was granted approval by the Australian and New Zealand governments for the treatment of ENL 
as well as for the treatment of relapsed and refractory multiple myeloma (Celgene, website).  
1.2 Chemical Properties 
Thalidomide, α-phthalimidoglutarimide or 1,3-dioxo-2-(2’,6’–dioxopiperidin-3’-yl) 





It has two ring systems, the phthalimide moiety on the left, and the glutaramide moiety 
on the right. Due to the asymmetry of the carbon atom (c*), on the glutaramide ring, thalidomide 
exists in optically active L and R isomers. In vivo, thalidomide inter-converts between isomeric 
forms to give an optically inactive racemic mixture. This inversion is very fast at 37 0C and is 
catalyzed by human serum albumin (Eriksson, T. et al, 1998). Thalidomide is insoluble in ether 
and benzene, sparingly soluble in water and ethanol and readily soluble in dimethyl sulfoxide 
(DMSO) and chloroform (The Merck Index, 1968). 
At a pH of 6.0 and above, the 4-amide bonds of thalidomide (indicated by arrows) 
become susceptible to OH- ions and undergo hydrolytic cleavage, yielding 4 major compounds, 
which undergo further breakdown to yield 8 compounds (Czejka, M.J. et al, 1987).  
1.3 Pharmacokinetics 
Thalidomide is absorbed slowly from the gastro-intestinal tract and is distributed 
throughout body fluids and tissues (Perri III, A.J. and Hsu, S., 2003). The pharmacokinetics of 
thalidomide has been studied in healthy as well as diseased individuals. With the exception of 
patients with Acquired Immuno-Deficiency Syndrome (AIDS), who may have gastro-intestinal 
absorption problems, thalidomide at a dose of 200 - 400 mg per os, achieves a peak plasma 
concentration of 1.15 – 3.44 mg/ml in 3 – 7 hours (hrs). The absorption half-life (T1/2) is 1.5 – 
1.7 hrs; whereas, the elimination T1/2 is between 6.5 and 8.7 hrs (Eriksson, T. et al, 2001).  
Thalidomide is mainly degraded by spontaneous hydrolysis in the blood and tissues. A minute 
quantity of the drug is also metabolized by the hepatic cytochrome P450 system (Mujagic, H. et 
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al, 2002). Thalidomide is not excreted renally as indicated by the presence of less than 0.7% of 
intact drug in urine (Eriksson, T. et al, 1998). 
1.4 Therapeutic Uses 
Due to its anti-inflammatory, immuno-modulatory and anti-angiogenic properties, 
thalidomide is an effective treatment for a variety of clinical conditions. Currently, the only FDA 
approved indication for thalidomide is in the treatment of ENL (FDA, 1998).  However, 
thalidomide has given promising therapeutic effects in various dermatological disorders like 
Behcet’s disease (Hamuryudan, V. et al, 1998), chronic lupus erythematosus (Stevens, R.J. et al, 
1997) actinic prurigo and prurigo nodularis (Perri III, A.J. and Hsu, S., 2003). It is also shown to 
be effective in Crohn’s disease (Odeka, E.B. and Miller, V., 1997). Thalidomide has also been 
used for the treatment of graft-versus-host-disease (GVHD) both in a murine model and 
subsequently in a phase II trial (Voglesgang, G.B. et al, 1989; Voglesgang, G.B. et al, 1992; 
Cole, C.H. et al, 1994). But attempts to use thalidomide as a prophylactic agent in the prevention 
of GVHD resulted in a paradoxical outcome with thalidomide treated patients having a higher 
incidence in GVHD and a lower overall survival (Chao, N.J. et al, 1996).  In complications 
related to HIV, thalidomide has been shown to treat wasting syndrome (Kaplan, G. et al, 2000), 
oropharyngeal, oesophageal and rectal apthous ulceration (Youle, M. et al, 1989; Jacobson, J. et 
al 1997), Mycobacterium Avium complex (MAC)–related infections (Bouza, E. et al, 1992) and 
microsporidial diarrhea (Sharpstone, D. et al, 1995).  
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1.5 Adverse Effects 
The most severe side effect of thalidomide is teratogenicity. Thalidomide can easily cross 
the placenta and affect normal fetus formation. A single dose of 50 mg tablet in the first trimester 
of pregnancy has been reported to cause birth defects. The principal defect observed in a fetus is 
phocomelia where the hands and feet are attached to abbreviated arms and legs due to a poorly 
developed limb. In severe cases complete absence of limbs have been recorded. Additional 
abnormalities may include malformations of ears, bones, face, eyes, gastro-intestinal and 
genitourinary tracts. About 40% of exposed fetuses die at or shortly after birth (Perri III, A.J. and 
Hsu, S., 2003). The S.T.E.P.S. program for fetus protection ensures that thalidomide will not be 
given to pregnant women (Zeldis, J.B. et al, 1999). 
Another potential adverse effect with prolonged use of thalidomide is peripheral 
neuropathy with risk of irreversible damage. This includes symmetrical, painful paresthesis of 
hand and feet often accompanied by numbness of lower limbs. Hypersensitivity reactions 
manifested by erythematous macular skin eruptions which if untreated could lead to fever, 
tachychardia and hypotension have also been reported. Somnolence and dizziness due to sedative 
properties of thalidomide have also been noted (Tseng, S. et al, 1996). Constipation can occur in 
some patients, which can lead to noncompliance if severe. Neutropenia is a rare side effect and is 
more common in HIV patients. In HIV-infected individuals, an increase in viral (median increase 
0.42 log10 per milliliter) load has been reported after administration of thalidomide for the 
treatment of oral aphthous ulcers (Jacobson, J. et al, 1997).    
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1.6 Thalidomide and Erythema Nodosum Leprosum (ENL) 
1.6.1 Historical Perspectives 
The ability of thalidomide to effectively treat ENL was accidentally discovered in 1965, 
shortly after its ban from the world market. Professor Jacob Sheskin, an Israeli Dermatologist 
and Leprologist, was confronted with a patient suffering with ENL. In order to appease the 
patient’s difficulty to sleep due to severe pain, Prof Sheskin gave him thalidomide as a sedative. 
Within 48 hours, he observed a significant improvement in the clinical manifestations of ENL. 
Prof. Sheskin reported his findings as an empirical study involving 6 ENL patients (Sheskin, J., 
1980). Thereafter, various well-controlled clinical trials have shown the efficacy of thalidomide 
in the treatment of ENL. All of these studies, including a multi-centered worldwide survey 
organized by the World Health Organization (WHO) showed an efficacy of thalidomide in ENL 
as high as 90-99 % (Sheskin, J. 1980). The recommended dose of thalidomide in the treatment of 
ENL is initially 100 mg 3 to 4 times a day and tapered to 100 to 50 mg/day for maintenance dose 
(Hastings, R.C., 1985). Thalidomide alleviates symptoms of ENL 1-2 weeks after initiation of 
therapy. Systemic symptoms like fever, malaise, arthritic and neuritic pains dissipate within 24-
48 hours after ingesting thalidomide. Disappearance of lesions takes relatively more time 
(Sampaio, E.P. et al, 1993) 
1.6.2 ENL 
ENL is an immunological reaction that occurs in 20 to 25 % of borderline leprosy and 
lepromatous leprosy patients. ENL occurs frequently after onset of treatment, but is also seen in 
untreated as well as treated patients (Petit, J.H.S. et al, 1967). ENL may be precipitated by 
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factors like pregnancy and parturition, protective immunization, stress, intercurrent infection and 
surgical operation (Jopling, W. H., 1988) 
The major symptom of ENL is the appearance of crops of painful erythematous nodular 
lesions, which persist for days and then subside. These skin lesions, which are distinct from 
existing leprosy lesions, are round or oval and mainly appear on the face, trunk and extremities 
(Job, C.K. et al, 1964). Peripheral neuropathy especially polyneuritis with risks of disability, is 
another major complication of ENL. Patients also have severe symptoms of fever and general 
malaise. Other complications include arthralgia, polyarthritis, irritis and orchitis (Job, C.K. et al, 
1964; Hastings, R.C., 1985).  
1.6.3 Histopathology 
ENL lesions are characterized with dense cellular infiltrates extending from lower dermis 
into sub-cutaneous fat (Job, C.K., et al 1964). At an early stage, lesions are characterized by a 
massive infiltration with polymorphonuclear neutrophils (PMN). As the inflammation subsides, 
the dominant cells in the lesion are lymphocytes and plasma cells. A slight increase in the 
number of histiocytes was also observed in chronic stages of ENL. The early stages of reaction 
also exhibit vasculitis due to swelling and edema of endothelium and to infiltration of blood 
vessel walls by PMN and eosinophils. The center of ENL lesions contain disintegrated 
histiocytes and fragmented and granulated acid-fast bacilli (Mabalay, M.C. et al, 1965; Ridley, 
M.J. and Ridley, D.S., 1983). 
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1.6.4 Immunology of Reactions in Leprosy 
During the course of their disease, leprosy patients exhibit two types of immunological 
reactions. Dr W.H Jopling classified these reactions as Type I or reversal reaction (RR) and Type 
II reaction or ENL (Jopling, W.H., 1971). This classification is different from that of Gell and 
Coombs, who categorized reactions into four types. Type I hypersensitivity reactions are caused 
by IgE and allergens in complexes on mast cells. This results in mast cells degranulation and the 
release of inflammatory mediators like histamine. Type II hypersensitivity reactions are caused 
by covalent interactions of small molecules, like degradation products of penicillin, with cell 
surface components producing modified structures recognized as foreign by IgG antibodies. 
Type III hypersensitivity reactions are initiated by soluble immune complexes that get deposited 
on walls of blood vessels. These initiate complement fixation with marked neutrophilic 
infiltration resulting in tissue injury. Type IV hypersensitivity reactions are cell-mediated and 
occur due to an emergence of effector T-cells that react with antigens resulting in responses that 
may include macrophage activation, cytokine production and cytotoxicity (Williams, E.P., 2003).  
In leprosy, reversal reaction (RR) mainly occurs in borderline leprosy patients and is 
caused by an increase in T-cell mediated immunity to M. leprae antigens expressed on dermal 
macrophages and Schwann cells. RR belongs to Type IV hypersensitivity group in the Gell and 
Coomb classification (Hastings, R.C., 1985). Clinical manifestations include a rapid change in 
the appearance of existing leprosy skin lesions, which become erythematous, more prominent, 
shiny and warm to touch. These lesions might sometimes break and ulcerate. A rapid swelling 
and inflammation of nerves with risks of motor disturbance is common. In RR, systemic 
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symptoms are very rare (Jopling, W.H., 1983). A transient influx of lymphocytes into lesions 
occurs at early stages. Edema around granulomatous lesions is very common. The cellular 
contents of granuloma changes progressively towards a more epitheloid form resulting in 
subsequent destruction of the bacilli within the granuloma (Ridley, D.S., 1969). RR is 
accompanied by an increase in the response and frequency of M. leprae-reactive T-cells in 
peripheral blood (Bjune, G. et al, 1976). Studies of skin lesions have demonstrated the 
infiltrating T-cells to be of CD4+ phenotype. These T-cells show a ten-fold increase in IFN-γ 
production, a cytokine that causes activation of macrophages with subsequent elimination of 
bacilli and the induction of delayed-Type Hypersensitivity reaction (DTH) (Cooper, C.L. et al, 
1989). 
ENL is thought to be caused by antibody as well as cell-mediated immune processes. 
ENL was initially proposed to be a Type III hypersensitivity reaction due to the similarity of 
some of its symptoms like albuminuria and erythema to those encountered in serum sickness or 
in the experimental Arthus reactions (Ulrich, M. et al, 1971). The formation of immune 
complexes may be expected in lepromatous leprosy due to the concomitant presence of large 
amount of mycobacteria and their corresponding antibody (Shannon, E.J. et al, 1981). The 
presence of fixed complement and immunoglobulin deposits in ENL lesions has been 
demonstrated (Wemambu, S.N. et al, 1969). However demonstration of immune complexes and 
complement products in circulation has been an elusive task in ENL. Complement activation in 
ENL has also been shown by an increase in the complement split product C3d in serum of 
patients with active ENL. Determination of immune complexes in plasma of these same patients 
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by C1q-binding activity revealed a poor correlation between these complexes and the C3d level. 
This strongly indicates that immune complexes in ENL are extra-vascular (Bjorvatn, B. et al, 
1976).  
An additional and unique characteristic in the leprosy patients experiencing ENL is a 
transient improvement in T-cell functions indicating the involvement of a cell-mediated 
component as well. During the acute stage of ENL an emergence of reactive T-cells was 
demonstrated as shown by an enhancement in mitogen as well as M. leprae-antigen-induced 
lymphocyte proliferation. (Laal, S. et al, 1985). Immunohispathologic studies using in situ 
immunoperoxidase staining have demonstrated that ENL lesions have an increase in the 
percentage of cells with receptors for IL-2 and an increase in CD4+ T-cells (Modlin, R.L. et al, 
1986; Sampaio, E.P. et al, 1993). In ENL lesions enhanced expression of intercellular adhesion 
molecules (ICAM-1), leukocyte function antigen 1 (LFA-1) (Sullivan, L. et al, 1991) and 
expression of major histocompatibility complex class II (MHC II) molecules on immune cells 
and keratynocytes have also been described (Thangaraj, H. et al, 1988, Sampaio, E.P. et al, 
1993).  
1.6.5 Possible Mechanisms of Action of Thalidomide in the Treatment of ENL 
Several studies have attempted to elucidate the mechanism of action of thalidomide in 
arresting ENL. Two main properties, anti-inflammatory and immunomodulatory represent the 
leading hypothesis regarding thalidomide’s mechanisms.  
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1.6.5.1 Effect on Phagocytic cells 
The influx of polymorphonuclear neutrophils (PMN) in early lesions and macrophages in 
ENL has prompted investigators to study the effect of thalidomide on chemotaxis, phagocytosis 
and effector mechanisms of phagocytic cells.  
1.6.5.1.1 Expression of Cell Adhesion Molecules and Chemotaxis  
In order to reach sites of inflammation, phagocytic cells in the blood must adhere and 
pass between the endothelial cells lining the walls of blood vessels. This migration process 
occurs in a step-wise fashion with the leukocyte rolling, tethering, adhering and then 
extravasation. These steps are mediated by interactions of cell surface molecules expressed on 
leukocytes and on vascular endothelial cells. Leukocyte rolling and tethering are mediated by 
selectins expressed on circulating leukocytes (L selectin) and on vascular endothelial cells (E and 
P selectins). Mucins, which are heavily glycocylated proteins, also interact with selectin in the 
initial phase of leukocyte adherence. A firm adhesion requires the interaction of integrins, such 
as LFA-1, Mac-1, and very late antigen-4 (VLA-4) expressed on leukocytes surfaces. Members 
of the immunoglobulin superfamily intercellular adhesion molecules (ICAMS) and vascular cell 
adhesion molecules (VCAM) pertain to distinct adhesion pathways. The ICAM-LFA-1 or Mac-1 
pathway is mediated by constitutively expressed ligands whereas the VCAM-1/VLA-4 pathway 
bind to cytokine stimulated endothelial cells. (Williams, E.P., 2003).  
Thalidomide’s ability to modulate the adhesion cascade was investigated as a possible 
mechanism of action for this drug. Thalidomide is shown to enhance the shedding of L-selectin 
from PMN and to down regulate the expression of the inducible receptor of VCAM-1, which 
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might to some extent explain its anti-inflammatory mechanism. But contrary to expectations, 
thalidomide enhanced the TNF-α-mediated expression of ICAM-1 indicating a rather complex 
mechanism of interaction (Geitz, H. et al, 1996). Thalidomide is also shown to enhance the TNF-
α-induced transmigration of PMN across a layer of human umbilical vein endothelial cells 
(HUVEC). It also synergized with TNF-α in the suppression of undirected as well as IL-8 and N-
formyl-methionyl-leucyl-phenylalanine (fMLP)-mediated PMN chemotaxis (Dunzendorfer, S. et 
al, 1997).  
1.6.5.1.2 Phagocytosis 
The effect of thalidomide on phagocytosis is variable. In an experiment involving the 
phagocytosis of small latex beads thalidomide exhibited a bimodal activity with enhancement of 
the phagocytosis by monocytes at a 1.0 µg/ml and suppression at 10 µg/ml; whereas for PMN, it 
only suppressed the phagocytosis at 10 µg/ml and failed to affect it at the lower dose (Barnhill, 
R.L. et al, 1984). Thalidomide failed to affect the phagocytosis of larger zymosan particles by 
PMN (Hastings, R.C. et al, 1978).  
1.6.5.1.3 Oxidative Effector Mechanism 
Thalidomide failed to affect the respiratory burst of PMN as shown by 
chemiluminescence experiments (Dunzendorfer, S. et al, 1997) as well as Nitro Blue 
Tetrazolium reduction assay  (NBT) (Golhman-Yahr, M. et al, 1978); whereas, 
chemiluminescence of monocytes was significantly depressed by thalidomide (Barnhill, R.L. et 
al, 1984).  
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1.6.5.1.4 Modulation of Cytokine Production by Thalidomide 
 TNF-α 
The presence of monocytes and lymphocytes in ENL lesions affords an opportunity for 
local production of inflammatory cytokines by these cells. TNF-α is one of the major cytokines 
produced by monocyte/macrophages. An enhanced level of TNF-α was detected in skin biopsies 
as well as in serum from ENL patients (Parida, S.K. et al, 1992; Moraes, M.O. et al, 1999). 
Thalidomide’s mechanism in treating ENL is thought to be associated with its ability to partially 
inhibit the production of TNF-α. This reduction in TNF-α was first demonstrated in vitro in 
endotoxin or M. leprae-stimulated human monocytes (Sampaio, E.P. et al, 1991) and then in vivo 
in thalidomide-treated ENL patients (Sampaio, E.P. et al, 1993). So far, three mechanisms of 
TNF-α suppression by thalidomide have been described: (1) thalidomide was shown to reduce 
the half-life of TNF-α messenger RNA (mRNA) from 30 to 17 minutes (Moreira, A.L., et al 
1993); (2) thalidomide is also shown to block NF-kB, a transcription factor involved in the 
regulation of several genes including TNF-α gene (Keifer, J.A. et al, 2001); (3) thalidomide is 
also shown to bind to α1-acid glycoprotein, a pro-inflammatory protein that belong to the acute 
phase proteins family (Turk, B.E. et al, 1996). 
The suppression of TNF-α by thalidomide in conditions other than ENL was observed in 
tuberculosis (TB) patients with or without a co-infection with HIV (Tramontana, J.M. et al, 
1985). 
The inhibitory effect of thalidomide on TNF-α became controversial when studies 
indicating an enhanced production of TNF-α by thalidomide, started to appear. In 1996, Shannon 
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et al showed thalidomide to enhance TNF-α production by LPS-stimulated human monocytes as 
well as in the LPS-stimulated THP-1-monocyte-like cell line (Shannon, E.J. and Sandoval, F., 
1996). This work supported subsequent findings of thalidomide-induced enhancement of TNF-α 
in the serum of apthous ulcers in HIV patients (Jacobson, J. et al, 1997) and in toxic epidermal 
necrolysis (Wolkenstein, P. et al, 1998). A recent study by Marriott et al has explained the 
varying effect of thalidomide on TNF-α as being conditional on the stimulant and the cell 
stimulated. In T-cell-independent systems like LPS-stimulated monocytes, thalidomide 
suppresses TNF-α; whereas, in a T-cell-dependent system such as PBMC stimulated by cross-
linking of T-cell receptor (TCR), thalidomide can enhance the production of TNF-α. This 
enhancement is seen at late stages of incubation (48-72 hours) and is thought to be dependent on 
IL-2 signaling (Marriott, J.B. et al, 2002). 
 Cytokines Other Than TNF-α 
The effect of thalidomide on the monocyte production of the pro-inflammatory cytokines 
IL-1 and IL-6 is not very clear. Thalidomide (0.1-10 µg/ml) was shown to have no effect on the 
production of IL-1β, IL-6 or granulocyte macrophage colony stimulating factor (GM-CSF) by 
monocytes from healthy humans stimulated with LPS (Sampaio, E.P. et al, 1991). On the other 
hand, the release of IL-1 by LPS-stimulated PBMC from TB patients was suppressed in 
thalidomide-treated patients. In this same study the in vivo treatment of TB patients with 
thalidomide failed to affect the plasma IL-1 level (Tramontana, J.M. et al, 1985). 
Thalidomide affects the production of IL-12 in a selective manner similar to its effect on 
TNF-α. In LPS stimulated monocytes, it suppressed the production of IL-12 (Moller, D.R. et al, 
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1997) whereas in T-cells stimulated via the TCR, it enhanced the production of IL-12 (Corral, 
L.G. et al, 1999).  
1.6.5.2 Modulation of Lymphocyte Activity by Thalidomide 
1.6.5.2.1 Lymphocyte Proliferation 
The effect of thalidomide on primary T-cell responses has been difficult to evaluate using 
lymphocyte proliferation assay. Treatment of antigen or mitogen stimulated peripheral blood 
mononuclear cells (PBMC) from healthy as well as HIV and/or TB patients has given 
inconsistent results.  Thalidomide given in vivo as well as in vitro in PBMC cultures from 
healthy individuals failed to affect lymphocyte proliferation in response to Concanavalin A 
(ConA) or purified protein derivatives (PPD) (Santos-Mendoza, T. et al, 1996). Günzler et al 
obtained a similar result in PBMC from healthy individuals stimulated with ConA and treated in 
vitro with 5 or 40 µMol/l (1.29-10.3 µg/ml) of thalidomide (Günzler, V. et al, 1986). In a study 
of tuberculosis (TB) patients with or without HIV co-infection, thalidomide treatment in vivo 
failed to significantly affect the ability of PBMC to proliferate in response to mycobacterial 
antigens (Tramontana, J.M. et al, 1985). Thalidomide at 3-30 ug/ml, failed to affect the ability of 
PBMC from a healthy individual to incorporate 3H-thymidine in response to phytohemagglutinin 
(PHA) and phorbol myristate acetate (PMA) (Fernandez, L.P. et al, 1995).  
Some studies have demonstrated thalidomide’s ability to suppress or stimulate the 
response of PBMC to various antigens and mitogens. Thalidomide suppressed the mitogenic and 
allogeneic stimulations of lymphocytes from healthy donors (Keenan, R.J. et al, 1991). In vitro 
treatment of thalidomide resulted in an enhanced proliferative response of PBMC from healthy 
 16
volunteers stimulated by cross-linking of the T-cell receptor (TCR) by immobilized monoclonal 
mouse anti-human CD3 antibody (Corral, L.G. et al, 1999). Similarly, in a study of whole 
PBMC as well as purified CD4+ and CD8+ T-cells from HIV-infected individuals, treatment with 
thalidomide at 1 and 10 µg/ml enhanced proliferative responses of these cells to anti-CD3 
antibodies (Haslett, P.A.J. et al, 1998). The varying effect of thalidomide on lymphocyte 
proliferation assay was recently explained to be dependent on the types of dominant cell 
population and the signaling pathway involved. In T-dependent systems, thalidomide act as a 
secondary co-stimulator required for optimal T-cell activation resulting in enhanced 
proliferation. This was demonstrated in PBMC stimulated with the T-cell receptor cross-linker 
anti-CD3 antibody, where thalidomide enhanced the proliferation of PBMC in a concentration 
dependent fashion (Marriott, J.B. et al, 2002; Corral, L.G. et al, 1999).  
1.6.5.2.2 T-cell Cytokine Production 
Thalidomide is shown to enhance the production of TNF-α in T-cell dependent systems. 
CC-4047 is an analogue of thalidomide classified as an ImiDs (immunomodulatory drugs). CC-
4047 is functionally similar to but more potent than thalidomide. A study involving CC-4047 has 
shown that the sources of elevated TNF-α are activated lymphocytes.  This thalidomide-induced 
production of TNF-α occurs as a late event and is dependent on IL-2–mediated signalling. 
Abrogation of the IL-2 signal by anti-IL-2 antibody disrupted the enhancement of TNF-α by  
CC-4047 (Marriot, J.B. et al, 2002). 
Several works have shown that thalidomide enhances the production of IL-2 by healthy 
as well as HIV-infected PBMC stimulated with mitogen and antigens (Shannon, E.J. and 
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Sandoval, F., 1995; Santos-Mendoza, T. et al, 1996; Marriott, J.B. et al, 2002; Haslett, P.A.J. et 
al, 1998). One particular group, which studied the expression of IL-2 by Jurkat cells, in response 
to PHA/PMA-induced stimulation, failed to demonstrate an effect of thalidomide on IL-2 
(Fernandez, L.P. et al, 1995).  
Thalidomide also enhanced the production of IFN-γ by mycobacterial antigen stimulated 
PBMC from thalidomide-treated TB patients (Tramontana, J.M. et al, 1985). A similar result was 
obtained in healthy individuals after ingestion of 400 mg thalidomide tablets where in vitro 
stimulation of PBMC with staphylococcal enterotoxin B (SEB) or anti-CD3 antibody resulted in 
a significant enhancement of IFN-γ (Verbon, A. et al, 2000).   
Thalidomide is also shown to slightly enhance the LPS-induced production of IL-10 by 
PBMC from healthy volunteers (Corral, L.G. et al, 1999). 
1.6.5.2.3 Effect on Plasma Cells and Antibody Production 
Although formation of complexes between M. leprae antigens and their corresponding 
antibody is described as an initial event in ENL, not much work has been done regarding the 
effect of thalidomide on humoral immune responses. Production of primary IgM response to 
sheep red blood cells (sRBC) was suppressed in Swiss Webster mice fed with a thalidomide 
containing diet for 5 to 7 days prior to sensitization with sRBC; whereas, assessment of 
secondary humoral immune response revealed no effect of thalidomide on anti-sRBC IgG. In this 
same study, a marked reduction in serum IgM was also demonstrated in LL patients treated with 
both thalidomide and dapsone compared to healthy individuals, untreated active LL patients as 
well as dapsone treated patients (Shannon, E.J. et al, 1981). An opposite finding was reported in 
 18
another study where B6C3F1 mice were treated with thalidomide and sensitized with sRBC 
intravenously (i.v.). Evaluation of direct anti-sRBC plaque forming cells indicated significant 
enhancement in spleen IgM level due to thalidomide treatment (Karrow, N.A. et al, 2000). The 
difference of these two works was the method of thalidomide preparation, administration and 
dose used. In the study by Shannon et al 1981, thalidomide was incorporated into a powdered 
diet at 0.03% w/w which is the concentration required to achieve 0.84 µg/ml, an amount 
equivalent to plasma thalidomide level obtained after intake of a100 mg tablet in humans. While 
Karrow et al mixed thalidomide with water and injected mice by the i.p route at 30-150 mg/kg.  
1.6.5.2.4 Effect on Lymphocyte Surface Expression Molecules 
Patients experiencing ENL have an increase in CD4+ cells in blood as well as in skin 
lesions (Modlin, R.L. et al, 1986). Thalidomide administration in vivo resulted in alteration of 
the ratio of CD4+: CD8+ cells in blood of healthy individuals (Gad, S.M. et al, 1985). A 
reduction in the total CD4+ cells and an increase in CD8+ cells were observed in thalidomide 
treated ENL patients (Shannon, E.J. et al, 1992). Treatment of ENL patients with thalidomide 
resulted in a prompt reduction in CD4+ T-cells in lesions. A reduction in the expression of MHC 
Class II antigen and ICAM-1 by epidermal keratinocytes was also reported (Sampaio, E.P. et al, 
1993). In vitro, treatment of PBMC with thalidomide and analysis of the expression of cell 
surface markers like CD2, CD4, CD5, CD8, HLA-A, B, C and HLA-DR molecules revealed no 
significant change (Shannon, E.J. et al, 1994). In HIV-infected individuals, treatment with 
thalidomide resulted in marked increase in soluble CD8 antigen in plasma while no change was 
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observed in soluble CD4 antigen. No significant difference was detected in CD4+ as well as 
CD8+ T-cell subsets between thalidomide treated group and placebo (Haslett, P.A.J. et al, 1998). 
1.7 Thalidomide in Cancer 
The immunosuppressive properties of thalidomide have led investigators to test this drug 
in the treatment of cancers as early as in the 1960’s.   The interest in the therapeutic potential of 
thalidomide in oncology quickly faded away as no dramatic effect was seen.  Recently this 
interest was rekindled when thalidomide’s anti-angiogenic activity was demonstrated (D’Amato 
J.R. et al, 1994). Angiogenesis or the formation of new blood vessels from already existing ones 
is crucial for the growth of tumors and for metastasis (Gupta, M.K. and Qin, R.Y., 2003).  
Several studies of thalidomide in the treatment of various cancers have been carried out.  
Multiple myeloma (MM) is one example with a dramatic response in patients that are refractory 
to conventional therapy (Singhal, S. et al, 1999; Tosi, P. et al, 2002). This drug recently received 
approval from the governments of Australia and New Zealand for the treatment of refractory 
multiple myeloma (www.Celgene.com). 
In MM, increase in bone marrow (BM) angiogenesis and an elevated BM plasma cell 
labeling index are associated with disease progression and poor prognosis. Conditioned medium 
of plasma cells isolated from MM patients showed a highly pronounced angiogenic activity in 
chick embryo chorioallantoic membrane, an enhanced chemotaxis and proliferation of 
endothelial cells (HUVEC) (Vacca, A.  et al, 1999). 
Malignant cells in MM are shown to secrete angiogenic cytokines known as endothelial 
growth factor (VEGF) and basic fibroblast growth factor (bFGF). VEGF is a potent inducer of 
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vascular permeability and a potent mitogenic activator of endothelial cells (Bellamy, W.T. et al, 
1999). Stimulation of bone marrow stromal cells from multiple myeloma patients with VEGF is 
shown to enhance the secretion of IL-6 a potent growth factor of myeloma cells. IL-6 is also an 
inhibitor of plasma cells apoptosis (Dankbar, B. et al, 2000). 
Thalidomide inhibited bFGF-induced angiogenesis in a rabbit cornea micropocket assay 
(D’Amato, J.R. et al, 1994). Successful treatment of refractory MM patients with thalidomide 
was demonstrated to be associated with a reduction in plasma VEGF (Kakimoto, T. et al, 2002). 
Thalidomide also suppressed the proliferation of HUVEC and inhibited the production of TNF-α 
by these cells (Moreira, A. et al, 1999). 
Interaction of integrins with the extra-cellular matrix of endothelium is important in 
endothelial cells survival, proliferation and migration during angiogenesis. The ability of 
thalidomide to suppress the β3 subunit of the αvβ3 integrin and to inhibit the release of FGF, 
which can stimulate the production of this integrin, suggests that thalidomide might modulate the 
expression of this integrin on endothelial cell surfaces (reviewed by Stephen, T.D. et al, 2000). 
But the inconsistent decrease in BM microvessel density (MVD) observed after treatment 
in MM patients (Kumar, S. et al, 2002a) has led to uncertainties regarding the importance of 
angiogenesis in MM.  This has led to investigations of other possible anti-tumor mechanism of 
thalidomide beside its anti-angiogenic effect (Kumar, S. et al, 2002b). Alternative anti-MM 
mechanisms such as the induction of plasma cell apoptosis, inhibition of TNF-α secretion by 
bone marrow stromal cells, modulation of T-cell immune response and induction of NK-cell 
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mediated lysis of malignant cells have all been investigated (Reviewed by Tosi, P. and Cavo, M., 
2002).  
In other hematological malignancies like acute myelogenous leukemia and non-Hodgkins 
lymphoma, thalidomide resulted in complete or partial response rates ranging from 20%-40%. In 
solid tumors like prostate, renal, brain cancers and Kaposi’s sarcoma, treatment with thalidomide 
resulted in a response rate ranging from 6 % to 47% (Kumar, S. et al, 2002a). 
1.8 Aim 
It has been almost 40 years since Professor Sheskin discovered thalidomide to be an 
effective drug for the treatment of ENL. Since that discovery, thalidomide has been used with 
successes and failures in the treatment of a variety of inflammatory condition especially those 
refractory to standard treatment with anti-inflammatory drugs.  
A precise mechanism of action for thalidomide is still lacking. Research efforts have 
pointed towards various possibilities but it has mostly been very hard to reproduce reported 
findings. The major sources of variation are the methods of drug preparation employed by each 
lab and the in vitro concentrations utilized. Thalidomide is poorly soluble in water and once in 
solution it quickly hydrolyses to different metabolic products.  
The objective of this study is to assess possible mechanisms of action of thalidomide by 
using a method of drug preparation that ensures minimum hydrolysis. The concentration of 
thalidomide used was within the range of physiological level achieved after ingestion of a 400 
mg tablet. 
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The controversial effect of thalidomide on primary T-cell response is rarely investigated 
in leprosy patients. In the first part of this work (part I), the effect of thalidomide on the immune 
response of PBMC from leprosy patients with or without reaction was investigated. The second 
part of this study (part II) assessed the effect of thalidomide on TNF-α production in patients 
with reversal reactions (RR). Although TNF-α level is elevated in RR patients, thalidomide has 
no therapeutic effect on this condition. This work was based on a finding from part I where 
thalidomide enhanced the production of TNF-α by PBMC from patients with borderline 
tuberculoid leprosy experiencing RR (BTRR) stimulated with integral M. leprae.  This finding 
was further investigated by using a statistically determined sample size of untreated RR patients. 
The production of TNF-α by PBMC stimulated with mycobacterial antigens and treated with 
thalidomide in vitro was quantitated at protein as well as mRNA levels.  
Thalidomide is shown to work in various inflammatory conditions while a convincing 
mechanism for its anti-inflammatory mechanism is still lacking. As the third chapter of this study 
(part III), the effect of thalidomide on the integrity of erythrocytes, PMNs and THP-1 cells 
membranes was studied.  
The last part of this study (part IV) assessed the anti-microbial action of thalidomide on 
intracellular M. leprae. Although some speculations exist regarding the direct effect of 
thalidomide on M. leprae, no work has been done so far to prove or disprove this. Intracellular 
bacilli in resting as well as activated mouse peritoneal macrophages were treated with 
thalidomide and the viability of M. leprae was investigated by radio-respirometric assay.  
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CHAPTER 2 THE EFFECT OF THALIDOMIDE ON THE IMMUNE RESPONSE OF 
CELLS FROM LEPROSY PATIENTS 
 
2.1  Introduction  
Leprosy is a chronic skin disease characterized by episodes of reactions. The cause of these 
reactions is unknown. They may occur during the normal course of the disease, during treatment 
and even after treatment when the patient is bacteriologically negative. They are classified as 
type I /reversal reactions (RR) or type II/ erythema nodosum leprosum (ENL). Although these 
reactions have different clinical manifestations, they share a similar immunological profile. The 
immune response in acute ENL (Laal, S.S. et al, 1985), as well as in acute RR (Bjune, G. et al, 
1976), is characterized in vitro by an enhancement in lymphocyte blast transformation to M. 
leprae antigen (s). These changes indicate the presence as well as the emergence of antigen-
reactive-T-cells in leprosy patients that are normally anergic to M. leprae.  
Among healthy individuals (Haslett, A.J.P. et al, 1998) and HIV positive patients 
(Shannon, E.J. et al, 2000), thalidomide has a stimulating effect on the ability of mitogen and 
antigen simulated T-cells to synthesize IL-2.  Since this cytokine is important in the evolution of 
events that culminate in the proliferation of lymphocytes, an objective of our study was to 
determine if thalidomide could modify lymphocyte blast transformation to M. leprae antigens.   
The mononuclear cells from patients attending the clinic at All Africa Leprosy, 
Tuberculosis and Rehabilitation Training Center (ALERT) for treatment of their leprosy or 
reactional episodes were exposed to thalidomide and to integral M. leprae, or antigens prepared 
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by sonication of integral M. leprae after depletion of lipids (a modified DHAR antigen), or to 
PPD prepared from M. tuberculosis. After 4 days in culture, the cells were pulsed with 3H-
thymidine and on day 5 the amount of tritiated thymidine incorporated by the cells was 
determined. 
2.2 Materials and Methods 
2.2.1 Study Subjects 
Ethiopian healthy staff employed at Armauer Hansen Research Institute (AHRI) (N=11), 
who are in frequent contact with leprosy and tuberculosis patients, and leprosy patients admitted 
to ALERT hospital for treatment of leprosy (N=33) were enrolled in the study. Fourteen of the 
patients were classified as having borderline tuberculoid leprosy (BT), eleven BT patients were 
experiencing reversal reaction BT/RR, and 8 patients with ENL. All of the ENL patients 
included in the study were being treated with steroids. This might have hindered the in vitro 
immune responses of mononuclear cells isolated from these patients.A signed written consent 
was obtained from each patient. All patients were evaluated by history and physical examination 
prior to preparation of mononuclear cell cultures.  
Table 2.1. Characterization of study groups 
 Age Range Sex  MDT* Anti-inflammatory+ 
  Male Female   
Healthy contacts N=11 25-56 7 4 0/11 0/11 
BT N=14 13-77 6 8 1/14 1/14 
BT/RR N=11 15-72 5 6 2/11 7/11 
ENL N=8 15-52 4 4 4/8 7/8 
* World Health Organization recommended multi-drug regimen, + Prednisone 
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2.2.2 Thalidomide  
Thalidomide was kindly provided by Dr. K. Zwingenberger (Grünenthal GmbH, 
Stolberg/Rhineland, Germany). The drug was dissolved in dimethylsulfoxide DMSO (Sigma, 
USA) and, within 5-10 min after diluting it in RPMI, it was added into appropriate wells. 
Thalidomide was used at 4.0 µg/ml in the cultures with a final concentration of DMSO of 0.25% 
v/v in thalidomide and control cultures. 
2.2.3 Antigens Prepared from Mycobacteria   
2.2.3.1 Mycobacterium Tuberculosis 
PPD RT 23 was kindly provided by Statenseruminstitut, Copenhagen, Denmark. The 
preservative-free PPD was diluted in RPMI to contain 20 µg/ml and distributed in wells in a 
volume of 50 µl for a final concentration of 5.0 µg/ml. 
2.2.3.2 Mycobacterium Leprae  
The antigens from M. leprae were prepared at the National Hansen’s Disease Programs, 
Laboratory Research Branch, Immunology Lab, Baton Rouge La. Integral M. leprae (acid-fast-
bacteria, AFB) was isolated from the tissue of nude mice infected with M. leprae. The tissue was 
aseptically removed from footpads of infected mice, and homogenized in 7H12 medium. The 
homogenate was centrifuged at 30 x g for 15 minutes (min). The pellet was discarded and the 
supernatant centrifuged at 2450 x g for 45 min.  The pellet was suspended in 20 ml of 0.1N 
NaOH. After 10 min, the alkali treated material was centrifuged at 2100 x g for 30 min.  The 
pellet was washed twice with pyrogen free distilled water and suspended in pyrogen free distilled 
water. One half of this preparation was frozen and used as the integral M. leprae (AFB). The 
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other half was prepared, as follows, for the DHAR antigen. Integral M. leprae was centrifuged at 
450 x g for 30 min. The pellet was suspended in 6 ml of chloroform and dried using nitrogen gas. 
The dried fraction was suspended in 6 ml of ether and centrifuged at 450 x g for 30 min. The 
supernatant was discarded and the bacteria suspended in ether and transferred to an agate mortar 
and worked to dryness with a spatula. The dried bacilli were suspended in 5.0 ml of pyrogen free 
distilled water, and disrupted by sonic oscillation, on ice, for 15 min at 30% duty cycle 
(Untrasonic Homogenizer 4710, Cole-Palmer Inst. Co., Chicago). The integral M. leprae were 
enumerated and numbers adjusted to contain 100 AFB bacilli/ 50 µl / 1 mononuclear cell. The 
DHAR preparation was assayed for content of proteins (DC Protein Assay, Bio-Rad), and added 
to the cell cultures in a volume of 50 µl. The final concentration was10 µg of protein /ml. 
2.2.4 Cell Cultures 
 Mononuclear cells were isolated from 30-40 ml of blood collected in Na-heparin-treated 
vacuum tubes. The blood was diluted to twice its volume with RPMI-1640 and centrifuged on 
Ficoll-Paque (Pharmacia, Uppsala, Sweden).  The mononuclear cells were harvested and washed 
three times in RPMI-1640 (Flow Labs, Irvine, UK).  The cells were adjusted to contain 2 x 106 
cells per ml RPMI-1640 that had been supplemented with 2 mM L-glutamine, 100 U/ml 
penicillin, 100 µg/ml of streptomycin and 10% v/v fetal calf serum (Sigma) (RPMI-10%).  One 
hundred µl of RPMI-10% containing 2 x 105 mononuclear cells was added into flat-bottom wells 
of a 96-well plate.  The control cultures and cultures not treated with thalidomide received 50 µl 
of RPMI-10% with DMSO at 1% v/v.  The cultures treated with thalidomide received 50 µl of 
RPMI-10% with DMSO at 1% v/v and thalidomide. The final concentration of unhydrolyzed 
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thalidomide was 4.0 µg/ml.  The final concentration of DMSO in all cultures was 0.25% v/v.  
The Control cultures, not stimulated with antigen, received 50 µl of RPMI-10%.  The cultures 
stimulated with antigens received 50 µl of RPMI-10% containing DHAR antigen, or integral M. 
leprae, or PPD (as described above).  
2.2.5 Assay for Lymphocyte Blast Transformation  
 The cells were incubated at 5% CO2 in a high humidity, 370C incubator. Culture 
systems were set up under two different conditions. One group, at the initiation of the 5-day 
culture period, received 4.0 µg/ml of thalidomide (1X). Another set of cultures, to insure a source 
of unhydrolyzed thalidomide during the pulse with 3H-thymidine, received 4.0 µg/ml of 
thalidomide for the second time on day 4 (2X).  On day four in the 2X thalidomide treated 
cultures, the concentration of unhydrolyzed thalidomide was estimated to be 4.0009 µg/ml with 
94 ng/ml of residual unhydrolyzed thalidomide remaining after the first 4 days in culture and the 
additional thalidomide added for the second time. This calculation was based on the estimated t½ 
of 8.0 hrs for thalidomide in tissue culture medium at 370C  (Gunzler, V. et al, 1986). 
 On day 4, the cultures were pulsed with 1µCi per well of H3-thymidine (Boehringer 
Mannheim, Germany). After 18 hours, cells were harvested on filters and the amount of 
radioactive thymidine incorporated into cellular DNA was determined using a Rack-β Liquid 
Scintillation Counter (LKB, Pharmacia, Uppsala, Sweden). The results were expressed as 
stimulation index (SI), which is the mean counts per minute (CPM) from three replicate cultures 
of the mycobacterial antigen alone or the mycobacterial antigen + thalidomide treated cells 
divided by the CPM of cultures not receiving antigen or thalidomide. 
 28
2.2.6 Determination of TNF-α 
On day 4, prior to the addition of thalidomide, 50 µl of supernatants was collected from 
each culture and frozen for later analysis of TNF-α. Commercial ELISA reagents were 
purchased (R&D Systems, Minneapolis) and used according to the manufacturer’s specifications. 
The amount of TNF-α in each sample was determined from the standard curve using the 
program KCjunior Version 1.31.2 (Bio-Tek Instruments Inc, Vermont). The concentrations of 
TNF-α in cultures were expressed in ng/ml.  
The percentage suppression of TNF-α was calculated from the following formula: 
% Suppression= [1- (TNF-α in thalidomide treated wells)] x 100 
                                     TNF-α in untreated cultures 
2.3 Results 
2.3.1 Proliferative Responses in the Absence of Thalidomide 
The modified DHAR and M. leprae antigen preparations were titrated for their ability to 
stimulate mononuclear cells to incorporate 3H-thymidine as described previously (Shannon, E.J, 
et al, 1984). Using mononuclear cells from two healthy lepromin and PPD positive individuals, 
the DHAR antigen preparation stimulated the cells at 10 µg/ml. After exposing the cells to a ratio 
of 1:1 or 10:1 or 100:1 M. leprae acid fast bacteria (AFB): mononuclear cells, the maximum 
stimulation with integral M. leprae was observed at a ratio of 100 AFB to 1 mononuclear cell 
(data not shown). 
  The mononuclear cells from the healthy staff, BT and BT/RR, in the absence of 
thalidomide, responded to the three antigen preparations with the rank of response to PPD > 
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DHAR> AFB. The patients in the ENL group were not stimulated as well to the M. leprae 
antigens. 
2.3.2 Effect of thalidomide on Proliferative Responses  
 Thalidomide (1X and 2X) did not alter the lymphoproliferative response to the 
mycobacteria antigens in the BT, ENL and healthy groups.    
 Thalidomide (2X) empowered the mononuclear cells from the BTRR patient group to 
incorporate [H3]-thymidine when stimulated with DHAR (Wilcoxon signed rank test p= 0.01) 
compared to thalidomide untreated cultures (Figure 2.1)  
Among the thalidomide 2X treated healthy cells, the addition of thalidomide for the 
second time resulted in a suppression of cell proliferation in response to PPD and AFB compared 
to thalidomide untreated cultures. This was shown by the significant decrease in SI (p=0.02 for 
PPD and p=0.01 for AFB). For the rest of the groups, replenishment of thalidomide in cultures 
did not affect the SI (Figure2.1).  
2.3.3 Effect of Thalidomide on Synthesis of TNF-α 
 Thalidomide resulted in a significant suppression of TNF-α production in culture 
supernatants from cells from healthy staff exposed to the modified DHAR antigen (p=0.0312) 
(Figure 2.2). A mixed effect was seen for the other groups with a trend of suppression in most 
cases. It is interesting to note that among the BT/RR study group, four of seven patients cells 
were stimulated to produce TNF-α when incubated with integral AFB and Thalidomide (Figure 




Figure 2.1. The Effect of Thalidomide Added at the Initiation of Incubation Period (1x) and 
Thalidomide Added a Second Time 24 hours Prior to Termination of 5 days Cultures (2x).  
P value derived from Wilcoxon signed rank test. A=PPD, No Thalidomide; A'=PPD + 
Thalidomide (1x or 2x); B=Dharmendra, No Thalidomide; B'=Dharmendra + Thalidomide (1x or 
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Figure 2.2 Effect of Thalidomide on TNF-α Production. Culture supernatants, from cells 
treated with thalidomide and antigen or DMSO and antigen, were used in ELISA to measure 






 In diseases like leprosy, where cell mediated immunity (CMI) plays an important role in 
protection as well as in development of reactions and subsequent complications, the in vitro 
response of lymphocytes from patients against mycobacterial antigens is correlated well with the 
clinical manifestations (Myrvang, B. et al, 1973). We studied the effect of thalidomide on the 
lymphocyte blast transformation of cells from leprosy patients with or without reactions in 
response to stimulation with mycobacterial antigens. 
In vitro studies on the immunomodulatory properties of thalidomide have for the most 
part been based on mitogen stimulated cells from healthy individuals. Primed antigen-specific 
cells from patients may give a completely different picture. The direction of the differentiation of 
naïve T-cells mainly depend on the dose and type of antigens and on the surrounding cytokines 
microenvironment. In this study we used mononuclear cells from patients harboring and 
sensitized to leprosy bacilli. 
 Type I reaction in leprosy is characterized by a sudden increase in cell mediated 
immune response to M. leprae antigens (Bjune, G. et al, 1976). Our results show proliferation of 
BT/RR patients’ cells in response to all three antigens compared to unstimulated controls. 
However thalidomide failed to alter the in vitro proliferative response of the same patients 
against mycobacterial antigens. 
 ENL patients’ cells have been reported to incorporate 3[H] thymidine in response to 
soluble and integral M. leprae antigens (Laal, S.S. et al, 1985). Although significant, this 
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response was relatively lower to that observed in tuberculoid leprosy patients. The ENL patients 
included in our study did not respond well to the M. leprae antigen preparations. These patients 
were being treated with prednisone (some as much as 30 mg per day) and were probably in a 
hyporeactivity or anergic phase usually observed in post-treatment of ENL. 
The DHAR treatment of mycobacteria is thought to improve the antigen recognition and 
immune cell response without affecting the antigenic constituents of the bacilli. This is well 
confirmed in our study where the response to DHAR antigen, be it in healthy staff or BT and 
BT/RR leprosy patients, is relatively better than that to integral bacilli.  
Thalidomide has been previously shown to enhance the DTH response to a challenge 
dose of PPD in individuals with PPD skin test positivity (Tramontana, J.M. et al, 1995). In vitro, 
the drug had been shown to increase synthesis of IL-2 in PPD positive individuals (Shannon, E.J. 
et al, 1995). In our study, thalidomide facilitated the response against DHAR in BTRR patients.  
 In various in vitro studies, the effect of thalidomide on the ability of antigen or mitogen 
stimulated cells to incorporate 3[H] thymidine is controversial. Among healthy PPD positive 
individuals in Mexico, it was found that thalidomide or metabolites of thalidomide did not alter 
the ability of cells stimulated with PPD to incorporate 3H- thymidine (Santos-Mendoza, T. et al, 
1996). Whereas, another study showed that the drug enhances the proliferation of TB and HIV 
co-infected patient’s cells stimulated with PPD (Bekker, L.G. et al, 2000). One possible 
explanation for such inconsistencies is the extremely quick hydrolysis of thalidomide. Even in a 
physiological environment like blood, thalidomide quickly hydrolyses. This characteristic of 
thalidomide is even faster at pH 7.0 to 7.5 (Ericsson, T. et al, 1998). The type of solvent used, 
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incubation times and pH of media determine the extent of hydrolysis and the type of metabolite, 
which will predominate in the assay (Shannon, E.J. et al, 1997). Our data might be the 
summation of the actions of different hydrolysis products of thalidomide.  
Parallel to the proliferation assay, the effect of thalidomide on the level of TNF-α was 
also assessed. Suppression of TNF-α was exhibited in healthy contacts in response to DHAR 
antigens. 
Despite several studies conducted for over a quarter of a century, thalidomide’s 
mechanism of action in arresting ENL is still unknown. This lack of understanding is 
accentuated by the uncertainties that still remain today about the factors which cause ENL. 
Treatment of a given clinical condition with thalidomide may be associated with a 
decrease in TNF-α like in ENL (Sampaio, E.P. et al, 1992) or an increase in TNF-α like in 
aphthous ulcers (Jacobson, J. et al, 1997). In a trial involving the use of thalidomide to treat toxic 
epidermal necrolysis, the work was discontinued due to an elevated drug-related toxicity. TNF-α 
levels were elevated in the patients who received thalidomide compared to the placebo group 
(Wolkenstein, P. et al, 1998). Comparison of prednisone, pentoxifylline and thalidomide in the 
treatment of ENL revealed that although thalidomide is the most effective drug to relieve this 
condition, prednisone suppresses TNF-α more than thalidomide. The level of TNF-α detected in 
ENL is so low that the authors suggested that this cytokine might not be the only factor 
responsible for the pathology of ENL (Moreira, A. et al, 1998). The most convincing evidence 
that TNF-α is not the sole cytokine targeted by thalidomide in ENL is the observation that this 
drug is not an effective treatment for reversal reaction (Hastings, R.C. et al, 1985). The 
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pathology of RR, even more so than in ENL is associated with an increase in TNF-α protein and 
TNF-α mRNA in the skin and peripheral nerves (Naffs, B., 1994; Khanolkar-Young, S. et al, 
1995).  
With the exception of cells from ENL patients, a fairly good stimulation in the presence 
of all three mycobacterial antigens was obtained without thalidomide treatment. Thalidomide 
resulted in a significant suppression in healthy controls in response to PPD and AFB antigens. 
In order to adjust for drug hydrolysis, thalidomide was added in cell cultures a second 
time. This replenishment caused an enhanced response to DHAR in the BTRR group whereas no 
effect was seen in the other groups.  
TNF-α production was suppressed only in the healthy control group in response to 
DHAR antigen. In the BT/RR groups, in four of the seven patients an enhancement of TNF-α 
production was observed in cells stimulated with integral M. leprae. Additional work is needed 
to confirm this interesting finding.  
 Overall a clear picture of the immuno-modulatory effect of thalidomide in leprosy was 
not obtained. ENL is one of the immune complications where thalidomide works best. With the 
presently growing number of indications for thalidomide, another approach, like phenotypic 
analysis of cell surface molecules, might result in a clearly demarcated effect to elucidate the 
mechanism of action of this drug in ENL. This will provide background information for the 




CHAPTER 3 THE EFFECT OF THALIDOMIDE ON THE EXPRESSION OF TNF-α 
MRNA AND THE SYNTHESIS OF TNF-α IN CELLS FROM LEPROSY PATIENTS 
WITH REVERSAL REACTION 
 
3.1 Introduction 
Leprosy is a spectral disease characterized by the severe form of lepromatous leprosy (LL) 
at one end of the spectrum and the milder tuberculoid leprosy (TT) at the other. Borderline 
leprosy patients lie between LL and TT and are immunologically unstable (Hastings, R.C., 
1985). This group of patients has a tendency to downgrade or upgrade their immune response to 
M. leprae with a consequence of adverse reactions. 
Reactions associated with an upgrading in the immune response to M. leprae are known as 
reversal reactions (RR). Symptoms of RR include inflammation of pre-existing lesions and acute 
neuritis with risks of permanent disability. The other type of immunological reaction in leprosy, 
known as erythema nodosum leprosum (ENL), is mainly confined to LL patients. ENL is 
manifested by the appearance of crops of tender erythematous nodules, neuritis and systemic 
symptoms like fever, myalgia and general malaise (Ridley, D.S., 1969). 
Common to both RR and ENL is a transient enhancement in cell-mediated immunity 
towards M. leprae (Bjune, G. et al, 1976; Laal, S. et al, 1985); an elevated production of TNF-α 
(Sarno, E.N. et al, 1991; Khanolkar-Young, S. et al, 1995; El-din, A. et al, 1998), with TNF-α 
reported to be even more elevated in RR (Gru, G. et al, 1992).  
Thalidomide is the drug of choice for the treatment of ENL, but it lacks any effect in the 
treatment of RR (Hastings, R.C., 1985). Thus the beneficial effect of thalidomide in ENL, which 
has been mainly attributed to an inhibition of TNF-α, does not explain why the drug is not 
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equally successful in the treatment of RR. We observed, among 4 of 7 steroid-treated RR 
patients, that thalidomide enhanced TNF-α when PBMC cultures were stimulated with integral 
M. leprae antigen (AFB) (Tadesse, A. et al, 2003). This study is an extension encompassing a 
larger non-steroid treated population of patients and also assesses mRNA expression for TNF-α 
in the cultured cells. 
PBMC from a group of 68 RR patients and two control groups were treated with 
thalidomide and stimulated with integral γ-irradiated M. leprae (AFB), a cytosolic preparation 
from M. leprae (MLSA) and DHAR antigen. Lymphocyte proliferation was determined by 
incorporation of 3H-thymidine; TNF-α was measured by ELISA, and TNF-α mRNA was semi-
quantitated using reverse transcription polymerase chain reaction (RT-PCR).  
3.2 Materials and Methods 
3.2.1 Study Subjects 
Based on previous observations with 4 of 7 RR patients having an enhanced TNF-α 
production due to thalidomide (Tadesse, A. et al, 2003), The sample size was calculated with a 
10% margin of error and a 90 % confidence level to be 68. The two control groups used were: 12 
borderline leprosy patients without reversal reactions (BT, BB and BL), and 15 healthy 
individuals with frequent contact with leprosy and tuberculosis patients. Patients were attending 
the clinic at All Africa Leprosy Rehabilitation and Training Center (ALERT). Those 
experiencing RR had blood drawn immediately upon admission and prior to treatment with anti-
inflammatory drugs. The subjects were informed about the purpose, possible risks and benefits 
of the study and a written signed consent was obtained from each subject. Only adults of 18 
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years and above were enrolled in the study. All patients were evaluated by history and physical 
examination and the clinical characteristics of each patient were recorded in table 3.1. 
Table 3.1. Characterization of Study Groups 
 Age Range Sex  Total 
  Male Female  
Patients with RR     
BT/RR 18-65 15 17 22 
Borderline lepromatous (BL/RR) 18-70 26 17 43 
Lepromatous (LL/RR) 18-65 3 0 3 
Patients without RR (Control 1)     
Mid-borderline (BB) 55 1 0 1 
BT 21-73 3 0 3 
BL 19-55 5 2 7 
Neural leprosy 60 1 0 1 
Healthy Individuals (Control 2)     
 24-45 9 6 15 
 
3.2.2 Thalidomide 
Thalidomide (kindly provided by Celgene, Warren, New Jersey) was dissolved in 
dimethylsulfoxide (DMSO). Within 5-10 min after preparation, dilutions were made in complete 
RPMI. As previously described, a concentration of 4.0 µg/ml of thalidomide was used (Tadesse, 
A. et al, 2003). [This concentration of thalidomide best approximates the area under the curve 
where thalidomide has been used effectively in the treatment of a variety of inflammatory 
conditions (Erikson, T., 1997)]. A concentration of 0.25% v/v of DMSO was maintained in all 
drug-treated and control wells. 
 39
3.2.3 Antigens 
 γ-irradiated integral M. leprae (AFB) and a cytosol fraction of M. leprae (MLSA) were 
kindly provided by an NIH awarded contract to Colorado State University (Department of 
Microbiology, CSU). The γ-irradiated bacteria were used at a final concentration of 25 µg/ml and 
the cytosol fraction of M. leprae (MLSA) was used at a final concentration of 25 µg/ml.  
The DHAR (DHAR) antigen was prepared from M. leprae at the Laboratory of the National 
Hansen’s Disease Programs in Baton Rouge, Louisiana as described previously (Tadesse, A. et 
al, 2003). Based on a determination of protein content, a final concentration of 5µg/ml was used 
in cultures.  
 Purified protein derivative PPD RT23 (Statens Serum Institut, Copenhagen, Denmark) 
contained a final concentration at 10µg/ml in cultures. Phytohemagglutinin (PHA) (Sigma, Saint 
Louis MI) was used at 10 µg/ml. 
3.2.4 Cell Cultures 
Thirty ml of blood was collected from the leprosy patients and controls. PBMC were 
isolated by gradient density centrifugation. Briefly, the blood was diluted with an equal volume 
of RPMI-1640 (Flow Labs, Irvine, UK) and centrifuged on Ficoll-PaqueTM (Amersham 
Biosciences AB, Uppsala, Sweden). Mononuclear cells were harvested and washed twice with 
RPMI-1640. The cell pellet was resuspended in complete medium (RPMI-1640 supplemented 
with 10 % fetal calf serum, 2mM glutamine, 100 µg/ml streptomycin and 100 U/ml penicillin) 
and cells were adjusted to contain 2 x 106/ml. One hundred µl of cells was added per well into 
tissue culture plates. The cultures treated with thalidomide received 50 µl thalidomide dissolved 
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in DMSO and further diluted with complete media. The control cultures, not treated with 
thalidomide, received 50 µl of complete RPMI containing DMSO. The final concentration of 
thalidomide was 4.0 µg/ml and the final concentration of DMSO in all cultures was 0.25% v/v.  
Wells stimulated with antigens received 50 µl of the above-described antigens while control 
wells received 50 µl of complete RPMI.  
3.2.5 Assay for Lymphocyte Blast Transformation  
 The cell cultures were incubated at 5% CO2, high humidity and 370C. For cells 
stimulated with mycobacterial antigens the cultures were incubated for 5 days; whereas, the 
cultures stimulated with PHA were incubated for 3 days.  
 On day four (day two for PHA treated cultures), cells were pulsed with 2µCi per well of 
H3-thymidine (Amersham, Sweden). After 18 hours, the cells were harvested on filters and the 
amount of radioactivity was determined using a Rack-β Liquid Scintillation Counter (LKB, 
Pharmacia, Uppsala, Sweden). A stimulation index (SI) was calculated. The SI is the mean 
counts per minute (CPM) from three replicate wells of antigen or antigen + thalidomide treated 
wells divided by the CPM of DMSO treated wells. The following formula was used to determine 
the percent suppression (% S) by thalidomide. 
% S = [1- (SI of thalidomide + antigen-treated wells)] x 100 
                     SI of DMSO+ antigen-treated wells 
[When the % S is a positive number suppression occurred; whereas, a negative number indicates 
enhancement]. 
3.2.6 Determination of TNF-α 
Separate cultures were set in parallel for TNF-α analysis. On day 4 of incubation, 50 µl 
 41
of culture supernatants were pooled from each of 3 wells and frozen at –700C for later TNF-α 
protein quantitation. The remaining cell suspension was collected in Nunc tubes (Nalgen Nunc 
International, Denmark) and snap-frozen in liquid nitrogen for determination of TNF-α mRNA 
by RT-PCR. 
3.2.6.1 TNF-α Protein Determination 
A human TNF-α commercial ELISA kit (Pierce Endogen, Woburn, MA) was used to 
quantitate TNF-α in culture supernatants from AFB, DHAR and MLSA treated cultures. The 
provided manufacturer’s specifications were strictly followed. The amount of TNF-α in each 
sample was determined from the standard curve using Genesis Lite Version 3.03 (Life Sciences 
UK, Ltd). TNF-α concentration, expressed in pg/ml, was used to calculate the percent 
suppression using the following formula:  
% S = [1- (TNF-α in thalidomide and antigen treated wells)] x 100 
                         TNF-α in drug free and antigen treated wells 
3.2.6.2 Determination of TNF-α MRNA 
Frozen cell pellets were thawed and total RNA was extracted by using the RNeasy RNA 
isolation kit (Qiagen, gmbH, Germany). The RNA was resuspended in RNAse free water and the 
concentration was determined by spectrophotometer at 260 nm. The total RNA per each sample 
was used to synthesize complementary DNA (cDNA) using the Omniscript Reverse transcription 
kit (Qiagen, gmbH, Germany).  The Reverse transcription (RT) mix consisted of 2 µl 10x buffer, 
2 µl dNTP mix, 2 µl oligodT primer, 1 µl RNAse inhibitor and 1 µl Omniscript reverse 
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transcriptase. The reaction was allowed to proceed in a Multi-block systems thermal cycler 
(Hybaid, Germany) at 370C for 1 hour, 93 0C for 5 minutes and kept at 40C.   
The newly synthesized c-DNA was transferred to a sterile tube. A 1:10 dilution of the c-
DNA was used to measure the concentration of nucleic acids at 260 nm and to check for protein 
contamination by 260/280 ratios. The c-DNA was adjusted to 0.1 µg/µl with DNAse free sterile 
water. Ten µl of cDNA (1 µg) was used as template in each PCR work (Multi-block systems 
software, Hybaid Germany). The TNF-α primer pair sequence (Johnson B.J. and McMurray 
D.N., 1994) 5´-CCTTGGTCTGGTAGGAGACG-3´ and 5´-CAGAGGGAAGAGTTCCCCAG 
was used for amplification. Normalization was done with the housekeeping gene glyceraldehyde 
3 phosphate dehydrogenase (GA3PD) (Villiger P.M et al 1990) primers 5´-
ATGCCAGTGAGCTTCCCGTTCAGC-3´and 5´-TGGTATCGTGGAAGGACTCATGAC-3´. 
Both TNF-α and GA3PD primers were synthesized at the Gene Lab of BioMMED, Division of 
Biotechnology and Molecular Medicine (Louisiana State University, Baton Rouge, LA).  The 
PCR milieu for each tube consisted of 25 µl master mix (HotStatTaqTM PCR, Qiagen, gmbH, 
Germany) 1.5 µl of GA3PD or 2.5 µl of TNF-α primers, 10 µl cDNA and 13 µl of sterile 
distilled H2O. For TNF-α, the PCR program used was 950C 15 min 1 cycle; 940C 1 min, 620C 1 
min, 720C 1 min 45 cycles; 720C 10 min final extension. For GAP3D the PCR program used was 
950C 15 min 1 cycle; 940C 1 min, 620C 1 min, 720C 1 min 35 cycles; 720C 10 min final 
extension. A mixture of 8 µl of each PCR product and 2 µl of loading buffer was resolved on 
ethidium bromide stained 1% agarose gel. Bands were visualized by a UV transilluminator and 
the gel pictures were analyzed by computer software (LabWork TM Version 3.00, Upland, 
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California). The maximum optical density (OD Max) was used to score the relative intensity of 
the TNF-α-specific bands against the glyceraldehype-3-phosphate dehydrogenase (GA3PD), 
which was used as a control to normalize the cytokine signals within and between samples.  
The percentage of TNF-α mRNA was calculated from the following formula: 
% TNF mRNA = OD Max of TNF-α specific band of the sample x 100 
          OD Max of GA3PD band for the same sample 
 
3.2.7 Analysis of Data 
GraphPad Prism version 4.00 (GraphPad Software, San Diego California USA) was used 
to analyze the data. Wilcoxon signed rank test was used to compare thalidomide treated to 
untreated groups. Differences were considered to be significant when the p ≤ 0.05, 2-tail test. 
3.3 Results 
3.3.1 Lymphocyte Proliferation 
Cell viability was assessed by 3-day stimulation with PHA. The CPM in the PHA 
stimulated cultures ranged from 493 to 103,077 in the RR patients, from 372 to 37,216 in the BL 
patients, and from 17,405 to 117,576 in the healthy individuals. Proliferation to the 
mycobacterial antigens was assessed after 5 days in culture. Fifty three percent of healthy 
individuals had a response with a SI above 2.0 for AFB, 93% for DHAR and 33% for MLSA.  In 
RR patients the proportion of responders was 13% for AFB, 47% for DHAR and 13% for 
MLSA. Overall, the proliferative responses in the RR group were lower than the healthy control 




Table 3.2. Proportion of Subjects with a Stimulation Index Above the Cut-off Value of 2.0 
 Antigens RR (n=68) No RR (n=15) Healthy (n=12) 
AFB 9 (13.2*) 2 (16.6) 8 (53) 
DHAR 32 (47) 0 14 (93.3) 
MLSA 9 (13.2) 1 (8.3) 5 (33.3) 
        
*Values in bracket represent percentages       
3.3.2 Effect of Thalidomide on Lymphocyte Proliferation 
The SI in drug free + antigen-treated wells with the SI in thalidomide + antigen-treated 
wells, inn the RR patient group thalidomide significantly enhanced proliferation in response to 
DHAR (p= 0.004) and MLSA (p= 0.013); it failed to significantly stimulate proliferation in 
response to AFB (p= 0.0629). Thalidomide also suppressed AFB induced proliferation among 
healthy controls (P= 0.0084) (Figure 3.1). In all of the groups, thalidomide did not significantly 
modify the response of PBMC to PPD (data not shown).  
3.3.3 Effect of Thalidomide on the Synthesis of TNF-α  
The TNF-α levels in drug free + antigen-treated wells with TNF-α in thalidomide + 
antigen-treated wells, in all the groups, thalidomide: suppressed the synthesis of TNF-α, in 
response to the antigen preparations from AFB, DHAR and MLSA (p < 0.0001) (Figure 3.2A). 
A similar suppression of TNF-α due to treatment with thalidomide was seen in healthy 
individuals (AFB p=0.0017, DHAR p= 0.0134 and MLSA p= 0.0266) (Figure 3.2B). For 
borderline leprosy patients without RR, the suppression was significant in the AFB (p=0.031) 




Figure 3.1. Effect of Thalidomide on Lymphocyte Proliferation to M. Leprae 
Antigens. PBMCs from leprosy patients with RR (A), patients without RR (B) and healthy 
individuals (C) were incubated with mycobaterial antigens and thalidomide for 5 days. At day 4, 
cultures were pulsed with tritiated thymidine. Counts per minutes were used to calculate SI, 
which are then used to determine the percentage enhancement (%E) or suppression (%S) by 




Figure 3.2. The Effect of Thalidomide on TNF-α Production. PBMCs from leprosy patients 
with RR (A), with leprosy patients without RR (B) and healthy individuals (C) were stimulated 
with AFB, DHAR and MLSA antigens for 4 days. Pools of 3 wells culture supernatant were used 
in ELISA to quantitate the level of TNF-α. The percentage suppression (%S) and enhancement 
(%E) were used as y intercepts.  
 
3.3.4 Effect of Thalidomide on TNF-α MRNA Level 
The TNF-α primers used were designed to span the junctions of 2 exons, making them 
specific for cDNA and not capable of recognizing contaminating genomic DNA (Johnson, 
B.J. and McMurray, D.N., 1994). As shown in Figure 3.3, the presence of TNF-α mRNA was 
validated by the presence of a 325 bp band in the agarose gels (Wang, A.M. et al, 1989). 
Although a fairly consistent cDNA band for TNF-α was detectable in almost all PBMCs in 
response to all three antigens (Figure 3.4), thalidomide did not significantly influence the TNF-α 
mRNA expression pattern in antigen stimulated cells (Wilcoxon signed rank test). The spread 
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was more pronounced among RR patients. GA3PD gave a fairly consistent band intensity of 190 
bp.  
   GA3PD            TNF-α  
 
       *   CT    A     AT    D    DT   M   MT                      *        CT  A   AT   D   DT     M     MT   
 
         *    CT A     AT    D     DT    M     MT                   *        CT  A    AT   D    DT  M    MT  
Figure 3.3. Effect of Thalidomide on TNF-α MRNA Expression. PBMC were stimulated with 
antigens for 5 days. Total mRNA was extracted; c-DNA synthesized and TNF-α mRNA 
expression was assessed by RT-PCR using specific primers. The housekeeping gene GA3PD 
was used for normalization. Lane legend: (*) molecular mass marker 123 bp DNA ladder, (CT) 
unstimulated cells + thalidomide, (A) AFB, (AT) AFB + thalidomide, (D) DHAR, (DT) DHAR 




Figure 3.4. The Effect of Thalidomide on the Expression of TNF-α MRNA in Antigen 
Stimulated Cells. Total RNA was extracted and used to synthesize cDNA. PCR was done using 
TNF-α specific primers. Values are normalized with the housekeeping gene GA3PD. A: AFB, 
A+T: AFB + thalidomide(T), D: DHAR, D+T: DHAR+T, M: MLSA, M+T: MLSA+T.  
 
 
3.3.5 Thalidomide-Induced Enhancement of TNF-α and TNF-α MRNA  
In 11 of the 68 RR patients, stimulation of PBMC with AFB antigen resulted in enhanced 
production of TNF-α (Table 3.4). These patients were of the BL/RR type with only one BT/RR 
patient. The SI was also enhanced due to treatment with thalidomide except for patients 1398/02 
and 360/03. Six out of 8 patients had a correspondingly enhanced expression of TNF-α mRNA. 
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Table 3.4. Characteristics of the Sub-Group of RR Patients with Enhanced TNF-α 
ID Age Sex RR Type * % E or S, SI * % E or S, TNF-α * % E or S TNF-α mRNA 
1329/02 60 F BL/RR -12 -12 -27 
1398/02 45 M BL/RR 26 -6 Not available 
049/03 18 F BL/RR -69 -4 -88 
165/03 60 F BL/RR -297 -6 Not available 
318/03 18 M BL/RR -18 -1 24 
347/03 40 F BL/RR -76 -28 Not available 
360/03 20 F BL/RR 8 -49 -47 
383/03 55 M BL/RR -109 -76 -39 
385/03 18 F BL/RR -109 -9 -13 
405/03 70 M BL/RR 22 -21 Not available 
422/03 32 M BT/RR -118 -2 -167 




Thalidomide has been shown to be effective in the treatment of pathologies associated with 
elevated TNF-α such as ENL (Sampaio, E.P. et al, 1993), and wasting syndrome in tuberculosis 
and HIV infections (Klausner, J.D. et al, 1996). This has been attributed mainly to the ability of 
thalidomide to suppress TNF-α (Sampaio, E.P. et al, 1993). There are, however, conditions such 
as toxic epidermal necrolysis where the rationale for using thalidomide to suppress TNF-α failed 
and an enhanced production of TNF-α was reported (Wolkenstein, P. et al, 1998). 
In RR, TNF-α was elevated even more so than in ENL (Gru, G. et al, 1992) in lesions as 
well as in the serum, yet thalidomide lacked any effect against this condition. Previously it was 
observed among steroid treated patients with RR that thalidomide induced an enhancement of 
TNF-α when mononuclear cells were stimulated with integral M. leprae (Tadesse, A. et al, 
2003). Non-steroid treated RR patients were studied to corroborate this observation and the 
influence of thalidomide on TNF-α in RR patients cells stimulated with mycobacterial antigens 
was assessed by measuring the expression of TNF-α mRNA in parallel with the synthesis of 
TNF-α.   
Cells stimulated with mycobacterial antigens, in the absence of thalidomide, gave an 
enhanced proliferative response in RR patients compared to patients without reaction. This 
confirmed the frequently described transient augmentation of cell-mediated immunity or the 
enhanced delayed type hypersensitivity (DTH) response to M. leprae antigens in RR (Bjune, G. 
et al, 1976; Cooper, C.L et al, 1989). Thalidomide co-stimulated the proliferative responses in 
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RR patients to the MLSA and DHAR antigens, but not to the AFB. The immuno-modulatory 
action of thalidomide has been shown to vary depending on the stimulant, the cells stimulated 
and the signalling pathway involved. The thalidomide-induced enhancement of proliferation of 
antigen specific T-cells in this study was similar to studies where PBMC were stimulated by 
cross-linking of T-cell receptor with anti-CD3. In these studies, thalidomide acts as a co-
stimulator resulting in enhanced proliferation of lymphocytes (Haslett, P.A.J. et al, 1998; Corral, 
L.G. et al, 1999; Marriot, J.B. et al, 2002).  
Among the RR group in response to DHAR and MLSA antigens and when comparing 
antigen stimulated cultures to antigen and thalidomide treated cultures, thalidomide enhanced 
lymphocyte proliferation but significantly suppressed TNF-α production. This is in contrast to a 
previous report by Marriot JB et al 2002 who showed that enhanced production of TNF-α is 
correlated with enhanced lymphocyte proliferation. In their study T-cells were stimulated 
directly by using anti-CD3 antibody; whereas, in this study, antigens derived from M. leprae that 
are likely to require processing and presentation to T-cell were.  
The effect of thalidomide on the expression of TNF-α mRNA in PBMC stimulated with 
the mycobacterial antigens was also assessed. Samples for the assessment of TNF-α and TNF-α 
mRNA were harvested at the same time but no correlation with a correspondingly consistent 
reduction of TNF-α mRNA with TNF-α was observed due to thalidomide treatment. When 
purified monocytes were stimulated with LPS, Moreira A., et al 1993 showed thalidomide to 
suppress TNF-α by reducing the half-life of TNF-α mRNA from 30 to 17 minutes. A likely 
explanation for this discrepancy is the varying effects of thalidomide related to the dominant cell 
 52
type and antigen used for stimulation (Marriot, J.B. et al, 2002). Alternative mechanisms of 
TNF-α suppression by thalidomide are blocking of NF-kB, a transcription factor involved in the 
regulation of several genes including TNF-α gene (Keifer, J.A. et al, 2001) and binding of 
thalidomide to α1-acid glycoprotein, a pro-inflammatory protein that belong to the acute phase 
proteins family (Turk, et al, 1996). 
Previous observation made among 4 of 7 RR patients of a thalidomide-induced enhanced 
production of TNF-α in response to stimulation with AFB was again observed in 11 out of 68. 
When comparing the effect of thalidomide in AFB stimulated PBMCs from all 68 RR patients, 
thalidomide failed to act as a co-stimulant. But, it did act as a co-stimulant in the subgroup of 11 
RR patients. In systems where thalidomide acts as a co-stimulator of T-cell activation, a 
subsequent induction of TNF-α was demonstrated (Marriot, J.B. et al, 2002). This co-stimulatory 
property of thalidomide is dependent on IL-2-mediated signalling indicating that T-cell 
activation rather than the direct effect of thalidomide resulted in increased production of TNF-α. 
One proof of IL-2-mediated signalling is an enhanced stimulation index in response to AFB in 8 
of these 11 RR patients. Although the level of IL-2 was not measured in this study, an 
augmentation of IL-2 by thalidomide was demonstrated by Shannon et al, (Shannon, E.J. and 
Sandoval, F., 1995) and confirmed by Haslett et al, (Haslett, P.A.J. et al, 1998).  
Cytokine secretion by T-cells is a transient process and requires activation of T-cells. 
Usually in T-cells, cytokine proteins and mRNA are not stored intra-cellularly but rather 
synthesized de novo. The transcription of these cytokines genes is highly regulated with most of 
their mRNAs having a short T1/2 (Lohning, M. et al, 2002). An exception to this rule is TNF-α, 
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whose mRNA is stored in resting cells in an unspliced form called pre-TNF-α. T-cell stimulant 
like anti-CD3 and PMA result in massive release of TNF-α, which is due to an induction of 
transcription of TNF-α gene as well as enhanced splicing of accumulated pre-TNF-α mRNA 
(Yang, Y. et al, 1998). Thalidomide might alter TNF-α at a post-transcriptional level by 
influencing the splicing of existing pre-TNF-α mRNA. Makonkawkeyoon et al, (1993) showed 
that the addition of thalidomide increased the amount of PMA-induced TNF-α mRNA in ACH-2 
cells- a T-cell line. If thalidomide acts as a co-stimulator as previously reported (Mariott, J.B. et 
al, 2002) it might also stabilize the mature TNF-α mRNA leading to increased production of 
TNF-α.  
The thalidomide-induced augmentation of TNF-α mRNA and TNF-α that was observed 
in cultures was limited to stimulation with integral M. leprae (AFB). Processing of the integral 
M. leprae antigen (AFB) by macrophages and Schwann cells and presentation of certain specific 
peptides might be responsible for activation of T-cells and enhancement of TNF-α production in 
RR.  
No striking in vitro parameter that can explain the absence of an effect of thalidomide in 
the treatment of RR was detected in this work. The pathogenesis of RR is the outcome of a 
complex interaction of antigen specific cell mediated immune responses and non-specific anti-
inflammatory events. The differential expression of the M. leprae antigens lipoarabinomanan 
(LAM) and phenolic glycolipd-1 (PGL-1) in lesions of RR patients (Verhagen, C. et al, 1999) 
and the concordant association of lymphocyte proliferation to M. leprae with the degree of 
inflammation among RR patients (Bjune, G. et al, 1976) are two examples of this complexity.  
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Unique to leprosy is the homing of the bacilli into Schwann cells. These cells have been 
shown to process and present M. leprae to MHC-II restricted CD4+ (Ottenhoff) and MHC-I 
restricted CD8+ T-cells (Steinhoff, U. et al, 1988). This dual property of the Schwann cell makes 
it a candidate for direct lysis by cytotoxic T-cell and probably explains the intense neuritis 
characteristic of RR. In an experimental autoimmune encephalitis (EAE) model using rats, 
thalidomide prolonged the duration of EAE and enhanced the inflammation of sciatic nerve 
(Zhu, J. et al, 1998). Similar to this model of T-cell-induced neuritis, the use of thalidomide in 
the treatment of RR may result in an exacerbation of the reaction. 
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CHAPTER 4 THE EFFECT OF THALIDOMIDE ON THE VIABILITY OF 
INTRACELLULAR M. LEPRAE IN ACTIVATED MACROPHAGES 
 
4.1 Introduction 
Thalidomide is the treatment of choice for erythema nodosum leprosum (ENL) (Sheskin, 
J., 1980). The sequence of events, which precipitate ENL as well as the exact mechanism by 
which thalidomide arrest ENL has not yet been clearly delineated.  The patients that may 
experience ENL during the course of their disease are those in the lepromatous end of the leprosy 
spectrum (lepromatous leprosy, LL and borderline lepromatous leprosy, BL) (Hastings, R.C., 
1985). These patients are characterized by the presence of precipitating antibodies in their sera 
and a tremendous load of mycobacterial antigen inside macrophages (Ridley, M.J. and Ridley, 
D.S., 1983). As the likelihood of an episode of ENL increases after the initiation of treatment, it 
has been suggested that release of M. leprae antigens from macrophages may be a factor, which 
initiates ENL (Hastings, R.C., 1985). The released antigen may then complex with antibodies, 
initiating complement fixation and production of inflammatory cytokines like TNF-α. 
Inhibition of TNF-α is one proposed mechanism by which thalidomide arrests ENL 
(Sampaio, E.P. et. al, 1991). However in a short open clinical study comparing the effects of 
thalidomide with other known inhibitors of TNF-α like pentoxifylline and prednisone, the 
authors concluded that thalidomide might have other targets in ENL (Moreira, A. et. al, 1998). 
Other evidence that TNF-α is not the sole cytokine targeted by thalidomide in ENL is the fact 
that thalidomide is not an effective treatment for reversal reaction (RR) (Hastings, R.C., 1985). 
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RR is another type of hypersensitivity reaction in leprosy where TNF-α is detected in skin and 
peripheral nerve lesions (Khanolkar-young, S. et. al, 1995). Depending on experimental 
conditions, and the type of cells stimulated, thalidomide may enhance or suppress the synthesis 
of TNF-α (Shannon, E.J. and Sandoval, F., 1996). Previous work has recently shown that 
thalidomide enhanced TNF-α in cells from RR patients stimulated with integral M. leprae 
(Tadesse, A. et. al, 2003). 
This report addresses a different tact in exploring the efficacy of thalidomide in treating ENL 
reactions. Could thalidomide actually be inhibiting the killing and breakdown of M. leprae and 
thereby inhibit the release of antigens? To study the effect of thalidomide on the fate of M. 
leprae in host macrophages, the viability of M. leprae residing in thalidomide-treated normal or 
IFN-γ-endotoxin activated mouse macrophages was assessed.  
4.2 Materials and Methods 
4.2.1 Source of M. Leprae 
Freshly isolated M. leprae from footpads of nude mice was used throughout the 
experiments (Ramesh, N. et al, 1991). In each of the experiments, the viability of 4 x 107 acid-
fast bacteria (AFB) was assessed by inoculating the M. leprae suspension into vials containing 
BACTECTM PZA Test Medium (Becton Dickinson Diagnostic System, Sparks, MD). The 
cumulative 14CO2 was measured daily for 7 days. 
4.2.2 Mouse peritoneal macrophages 
Macrophages were isolated from the peritoneal cavities of retired female Swiss Webster 
breeder mice (Simonsen Labs, Gilroy, CA). Briefly, 15 ml of cold heparinized phosphate 
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buffered saline (PBS) was injected into the peritoneal cavity of each mouse. The peritoneal 
exudates was collected and washed. The cell pellet was resuspended in 10 ml of Complete 
Medium (RPMI 1640, 50 µg/ml ampicillin, 2 mM glutamine, 10% fetal bovine serum). Cells 
were counted and adjusted to 4 x 106 per ml. The cell suspension was dispensed at 0.5 ml/well in 
24-well plates containing LUX ® plastic cover slips (Miles Laboratory, Naperville, IL). The 
plates were incubated overnight in a humidified incubator at 37 0C, 5% CO2. Non-adherent cells 
were washed off by dipping coverslips in sterile PBS and draining excess liquid on sterile 
gauzes. The coverslips were placed in another 24-well plate containing 0.5ml/well Complete 
Medium.  
4.2.3 Treatment Conditions 
Thalidomide was provided by Celgene (Warren, NJ) and was dissolved in a solution of 
0.85% NaCl, pH 3.0 (Acid Saline, AS) as described previously (17). A stock solution of 50 
µg/ml was aliquoted and kept in –70 0C freezer. Shortly before each experiment, dilutions of 
thalidomide at concentrations of 0.625 µg/ml, 1.25 µg/ml, 2.5 µg/ml and 5 µg/ml were done in 
AS. Based on the previously estimated half-life of 8.0 hrs for thalidomide in tissue culture 
medium at 370C (Gunzler, V. et al, 1986), cultures were replenished with 50 µl of AS containing 
thalidomide or 50 µl of AS daily to maintain an estimated concentration of ≥ 1.0 µg/ml of un-
hydrolyzed thalidomide in the 5 µg/ml treated cultures.  
4.2.4 Activation of Macrophages - Infection - Treatment with Thalidomide 
Monolayer cells on coverslips were incubated for 8 hours with 200 Units/ml of mouse 
recombinant IFN-γ (R and D Systems Inc., McKinley, MN) and 2.0 ng/ml of endotoxin (Sigma, 
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St Louis, MO). Coverslips were washed as described previously and placed in fresh Complete 
Medium. Viable M. leprae (4 x 107) was added into the resting or activated macrophage 
monolayer at an estimated 20:1 bacilli: macrophage. After an overnight incubation at 330C, non-
phagocytosed bacilli were removed by washing the coverslips. The infected macrophages were 
incubated with the different concentrations of thalidomide and controls. Drug and media was 
replenished daily for 7 days in the non-activated cultures and 3 days in the activated cultures. A 
shorter exposure to thalidomide in the activated macrophages was necessary as the cells were 
observed to detach after 3 days. 
4.2.5 Assessment of M. Leprae Viability: Radiorespirometric Assay 
A modified Buddemeyer radiorespirometric assay was used to assess the viability of M. 
leprae released from macrophage as described previously (Ramesh N. et. al., 1991). The 
coverslip containing the macrophage monolayer was placed in 400 µl of 0.1 N NaOH solution. 
Three hundred µl of the lysate was gently mixed and transferred to a sterile glass vial containing 
4.0 ml of PZA Test Medium with 1.0 µCi of [1-14C] palmitic acid and 50 µg/ml ampicillin. The 
vials with loosen cap were placed within PolyQ polyethylene vials containing a dried strip of 
Whatman DE42 filter paper (Whatman, Inc., Clifton, NJ). The paper had been dipped in a 
mixture of Liquifluor PPO-POPOP [2,5 diphenyloxazole-1, 4-bis (5-phenyloxazoly) benzene] 
toluene concentrate (New England Nuclear, Boston, MA) Triton X-100 and 4.0 N NaOH-
methanol. The strips were dried and kept at room temperature in a canister protected from light. 
The PolyQ vials with tightly closed cap were incubated at 330C. The generation of radioactive 
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14CO2 was determined daily by reading in a Beckman model LS-6000IC liquid scintillation 
counter. Data are presented as cumulative counts per minutes (CPM). 
4.2.6 Assessment of TNF-α in Activated Macrophages 
Twenty-four hours after thalidomide treatment of activated and infected macrophages, an 
aliquot of the culture supernatant was removed and frozen at -70 0C.  TNF-α was measured by 
using a mouse TNF-α immunoassay kit according to the manufacturer’s specification 
(Quantikine, R&D Systems, Minneapolis, MN). The amount of TNF-α in each sample was 
determined from the standard curve using KCjunior Version 1.31.2 (Bio-Tek Instruments Inc, 
Vermont).  
4.2.7 Nitrite Assay 
NO2- levels in culture supernatants were determined as described previously (Drapier, J.C. 
et al, 1988). Briefly, Griess reagent was prepared and dilutions of NaNO2 solution were used as a 
standard. All samples were assayed in duplicate. Samples were culture supernatants of activated 
macrophages treated with thalidomide for 24 hours and collected as described for TNF-α. 50 µl 
of standard and samples were dispensed into wells of a 96 well flat bottom tissue culture plate. 
Duplicate blank wells with media alone were also included in the experiment. 100 µl of Griess 
reagent was added into each well. The plate was mixed by gently tapping and incubated at room 
temperature for 20 minutes. Absorbance was read at 543 nm. The amount of NO in each sample 
was determined from the standard curve using KCjunior Version 1.31.2 (Bio-Tek Instruments 
Inc, Vermont).  
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4.3 Results 
4.3.1 Assessment of Metabolic Activity of Intracellular M. Leprae  
Prior to infecting the macrophages the viability of M. leprae used for each experiment 
was tested by inoculating into Pyrazinamide (PZA) test medium. At day 7, the cumulative mean 
+/- SD from 4 experiments was 36,344 +/- 3,801.  
Bacilli recovered from non-activated macrophages had a higher 14CO2 level (CPM range 
day 1- day 7:  2989 +/- 1391 to 7582 +/- 5481) compared to IFN-γ and LPS activated 
macrophages (CPM range day 1- day 7:  1488 +/- 324 to 3318 +/- 1129) (Figure 4.1). The 
difference between activated and resting macrophages was significant for all days except day 7 
(unpaired T test, GraphPad Prism V 4.0).  
 
Figure 2. Viability of M. Leprae in Activated Versus Resting Macrophages. Resting (open 
bar) and IFN-g -LPS-activated (hatched bar) mouse peritoneal macrophages were infected with 
M.leprae for 24 hours. Bacilli released from lysed macrophages were incubated in PZA test 
medium and14CO2 was quantitated daily for 7 days.  Mean CPM+/- SD of 3 to 8 replicates. 
Unpaired t test,* p< 0.05,** p< 0.01. 
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4.3.2 Effect of Thalidomide on Viability of M. Leprae  
Over a 7-day period, a gradual daily increase in 14CO2 was observed in the AS-treated 
control cultures and the thalidomide-treated wells at 0.625, 1.25, 2.5 and 5 µg/ml. There was no 
demonstrable titrated effect of thalidomide (data not shown). Figure 4.2 summarizes the 
cumulative mean CPM +/- S.D from 3 separate experiments on day 7 for thalidomide at 5 µg/ml. 
Comparison of the drug-free control group to the thalidomide treated groups in non activated as 
well as activated macrophages revealed no significant difference (unpaired T test).  
 
Figure 4.2. Effect of Thalidomide on Viability of M. Leprae Recovered From Non-
Activated and Activated Mouse Peritoneal Macrophages. Infected mouse peritoneal 
macrophages were treated with 5 µg/ml of thalidomide (Thal 5) and acid saline (AS). Cells were 
lysed and the viability of released bacilli was assessed by determining counts per minute (CPM) 
of cummulative 14C02 released. Open bars represent non-activated macrophages, closed bars 
represent activated macrophages. Means +/- SD from 3 separate experiments.    
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4.3.3 TNF-α and Nitrite Levels in Activated Macrophages 
After 24 hours exposure to thalidomide, no significant changes in TNF-α and NO2- was 
observed compared to media or AS controls. Although TNF-α levels were higher in thalidomide 
treated cells (24.8 pg/ml +/- 3.47) compared to AS-treated ones (18.12 pg/ml +/- 8.2), it was not 
statistically significant (Figure 4.3). 
 
 
Figure 4.3. Nitrite and TNF-α Levels in M. Leprae-Infected LPS-IFN-γ-Activated 
Macrophages. Activated mouse peritoneal macrophages were infected with viable M.leprae and 
treated with thalidomide at 5 µg/ml for 24 hours. Nitrite (A) and TNF-α (B) in culture 
supernatants were quantitated. Mean and SD for 4 replicate wells controls; M= media, AS= acid 
saline and T5= thalidomide. 
 
4.3.4 Morphological Appearance of Peritoneal Macrophages 
Breakdown products of thalidomide have been described to inhibit the attachment of cells 
to plastic surfaces (Braun, A.G. and Weinreb, S.L., 1984). For visual inspection of attachment of 
cells, coverslips from each treatment were stained with quik-Diff® (Dade Diagnostics, Aguada, 
PR), dried and mounted on microscopic slides.  
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The density of the cells appears to be the same in all the treated groups. Activated cells 
had a spindle-like shape and are clearly different than non-activated cells. Thalidomide treated 
activated macrophages were not morphologically different than AS treated activated 
macrophages (Figure 4.4). 
 
Figure 4.4. Monolayers of Mouse Peritoneal Macrophages. 
(A) Media control, non-activated 
(B) LPS + IFN-γ-activated and M. leprae Infected 
(C) LPS + IFN-γ-activated, M. leprae infected and thalidomide-treated 




In diseases like leprosy, a cell-mediated immune response plays a major role in the 
outcome of infection. The key components of this response are macrophages and T-lymphocytes.  
Killing of M. leprae by activated macrophages is the main mechanism of elimination of the 
bacteria (Sibley, D. et al, 1987). ENL is characterized by the detection of granulated beaded 
bacteria indicating a massive release of M. leprae by macrophages (Ridley, M.J. and Ridley, 
D.S, 1983). Although thalidomide is an effective treatment for ENL, the mechanism by which it 
alleviates this reaction is not fully understood. It is possible that drugs like thalidomide, 
depending on their concentration, may enhance local production and release of TNF-α into the 
microenvironment of the ENL skin lesion and facilitates remodeling of inflamed tissue. When 
TNF-α is produced in lesser quantities and in a timely fashion, it mediates a variety of anti-
inflammatory events promoting wound healing and remodeling of injured tissue (Vlassara, H. et 
al, 1988) and suppressing neutrophil migration (Otsuka, Y. et al, 1990). 
The anti-inflammatory and immunomodulatory properties ascribed to thalidomide offer 
multiple potential sites of action in arresting ENL. In this work we have tried to study whether 
thalidomide modulates the anti-microbial action of host macrophages against intracellular M. 
leprae as a possible prelude to inhibiting the release of mycobacterial antigen. 
Non-activated mouse peritoneal macrophages infected with M. leprae were treated with 
0.625-5.0 µg/ml of thalidomide for a week. Thalidomide failed to show a dose-response 
relationship and failed to alter the metabolic activity of M. leprae in a significant manner. Higher 
 65
concentrations of thalidomide may have shown a different result; however, the concentration of 
5.0 µg/ml was, considered to be, more relevant to that achieved in the treatment of ENL.  
These findings concur with previous studies on the in vitro as well as in vivo anti-
microbial action of thalidomide against other pathogens. Although thalidomide was effective in 
alleviating clinical symptoms associated with Mycobacterium Avium Complex (MAC) in HIV 
patients (Bouza, E.R. et al, 1992), in vitro it was unable to kill laboratory-cultured strains of 
MAC (Vicente, T. et al, 1993). Thalidomide is also effective against microsporidial diarrhea, but 
when tested in vitro, it failed to kill intracellular microsporidia (Ridoux, O. et al, 1999). In 
murine experimental tuberculosis (Moreira, A.L. et al, 1997) and BCG infection (Fazal, N.L. et 
al, 1988) models, thalidomide did not significantly alter bacterial load in organs. 
For efficient activation of M. leprae burdened macrophages, in addition to a primary 
stimulatory signal delivered by IFN-γ a secondary signal like endotoxin is required (Krahenbuhl, 
J.L. et al, 1990). The peritoneal macrophages were co-stimulated with IFN-γ and LPS.  In the 
absence of thalidomide, the cumulative 14CO2 from activated macrophages was higher than that 
of non-activated macrophages confirming previous findings where activated mouse peritoneal 
macrophages killed or inhibited M. leprae more effectively than non-activated macrophages 
(Adams, L.B. et al, 2000).  When tested in this activated macrophage system, thalidomide did 
not modify the viability of M. leprae in a significant manner. 
The effect of thalidomide on TNF-α produced in IFN-γ- LPS- activated-M. Leprae-
infected macrophages were also examined. Although statistical analyses revealed no significant 
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difference between TNF–α level from thalidomide and from AS treated cells, a higher level of 
TNF-α was observed in the thalidomide treated group.  
Reactive nitrogen intermediates, especially nitric oxide (NO) constitute a major anti- 
microbial effector armature of activated mononuclear phagocytes with activities against a broad 
spectrum of pathogens (Hibbs, J.B. et al, 1987).  A reduction in the viability of M. leprae occurs 
when activated mouse peritoneal macrophages produce a high level of NO (Adams, L.B. et al, 
2000). In this study, although the level of NO2- produced was similar to that reported by others, 
thalidomide failed to influence the production of this molecule.  
This work showed that thalidomide does not possess a direct anti-microbial action against 
intracellular M. leprae in normal or activated macrophages. Nor did it alter the production of 
TNF-α and NO in a significant manner. A distinct sequence of events explaining the mechanism 
of action for thalidomide to successfully treat ENL has yet to be established.  
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The anti-inflammatory properties of thalidomide are demonstrated by its beneficial effects 
in the treatment of inflammatory conditions like erythema nodosum leprosum (ENL), which may 
occur in leprosy patients, and apthous ulcers which may occur in AIDS patients (Zwingenberger, 
K. and Wendt, S., 1996; Tseng, S.P. et al, 1996). The sequences of events that precipitate these 
inflammatory conditions as well as the molecular and biochemical basis for the anti-
inflammatory properties of thalidomide are not understood. A common finding in the lesions of 
patients experiencing ENL or apthous ulcers is an influx of polymorphonuclear neutrophils 
(PMN) (Mabalay, M.C. et al, 1964; Burns, R.A. et al, 1985). Reactive oxygen species (ROI) 
produced by the PMN are important in intracellular killing of pathogens; however these ROI can 
also combine with enzymes released from lysosomes causing tissue damage and inflammation of 
the surrounding extra-cellular environment (Parham, P., 2000). 
 Stabilization of lysosomal membranes by thalidomide could be a mechanism for its anti-
inflammatory action in ENL.  Hastings showed that in vitro thalidomide prevented the release of 
B-glycerophosphatase from lysosomes isolated from rat livers. The drug was effective at 
concentrations similar to those achieved in the blood of leprosy patients effectively treated for 
their ENL (Hastings, R.C., 1971). Based on this interesting finding, the effect of thalidomide on 
cell membrane integrity was studied. 
 For stabilization of erythrocyte membrane, we used a modification of Dacie’s osmotic 
fragility test (Dacie, J.V., 1975). This test measures hemoglobin released from lysed RBCs after 
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their exposure to hypotonic solutions of sodium chloride (NaCl). The in vitro as well as in vivo 
effects of thalidomide on hemolysis of RBCs from healthy humans were investigated. To probe 
the effect of thalidomide on the stability of membranes of inflammatory cells, human PMNs and 
the human-monocytic cell line THP-1 were employed. The detection of lactic acid 
dehydrogenase (LDH) released in culture supernatants as a result of leakage was used as an 
indicator of membrane dysfunction.  
5.2 Materials and Methods 
5.2.1 Preparation of Thalidomide 
The drug for in vitro and ex vivo use was provided by Celgene and dissolved in acid 
saline (AS) as previously described (Shannon, E.J., et Al, 1997). AS was chosen as the solvent 
for thalidomide rather than the commonly used DMSO. This is due to reported interference of 
DMSO with cell metabolism and membrane integrity resulting in cellular damage (Penninck, F. 
et al, 1983).  
5.2.2 In Vitro Thalidomide Treatment 
Ten ml of peripheral blood was collected in a Na-heparin vacuum tube from 12 healthy 
adult volunteers by venipuncture. The blood sample was equally divided into 2 tubes. One tube 
of blood was centrifuged at 913 x g, at room temperature for 10 minutes. The plasma was 
removed and replaced with an equal volume of AS (normal saline, pH 3.0). The tube was labeled 
Washed RBC. The second tube containing the plasma was labeled Not Washed RBC. 
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5.2.3 Ex Vivo Thalidomide Treatment 
Sixteen healthy male volunteers were included in this part of the study. Twelve received 
drug and 4 received placebos. A blood sample was taken prior to ingestion of a 100 mg tablet 
and after the subject has consumed a cumulative dose of 600 mg of thalidomide given as one 100 
mg tablet every 4 hours. The blood was directly used (at 10 µl/well) in osmotic fragility 
experiments. 
5.2.4 Osmotic Fragility 
For convenience, Dacie’s method (Dacie, J.V., 1975) of osmotic fragility was modified to 
a micro-scale assay. Briefly, a 100 ml of a stock buffered NaCl solution containing 9 g of NaCl; 
1.365 g of Na2HPO4 and 0.215 g of NaH2PO4.H2O was prepared. A 1% solution of buffered 
NaCl was prepared by diluting the stock NaCl in deionized water. In a 96-well V-bottom 
microtiter plate, the dilution scheme in Table 5.1 was used to prepare hypotonic solutions.  
Table 5.1. Dilution Scheme of NaCl and Water to Give the Various % Salt Concentrations  
Dilution 1% buffered NaCl (µl) Deionized water (µl) Final NaCl Concentration % 
1 200 0 1.00 
2 170 30 0.85 
3 150 50 0.75 
4 130 70 0.65 
5 120 80 0.60 
6 110 90 0.55 
7 100 100 0.50 
8 90 110 0.45 
9 80 120 0.40 
10 70 130 0.35 
11 60 140 0.30 
12 40 160 0.20 
13 20 180 0.10 
14 0 200 0.00 
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The final volume in each well was 200 µl, 3 to 6 replicate wells were used for each 
concentration of salt. Ten µl of ThalW or ASW or Thal or AS treated blood was added into each 
well and the plate was incubated for 30 minutes at room temperature.  At the end of incubation, 
the plates were spun at 913 x g, at room temperature (RT) for 5 minutes. 100 µl of supernatant 
was carefully transferred from each well into wells of a clean flat bottom microtiter plate. The 
extent of hemolysis was determined by reading the plate in an ELISA reader (Synergy HT Multi-
detection microplate reader, Biotek) at 550 nm. Optical density (OD) readings were analyzed by 
using the software KC4 Version 3.0 ELISA Program (Biotek, Vermont). 
The percentage of hemolysis was calculated from the following formula: 
% Hemolysis =.       OD of the specific NaCl concentration                  . 
                               OD of 100% hemolysis (0% NaCl) 
For each drug treatment, osmotic fragility curves were prepared by plotting % hemolysis 
versus % NaCl in GraphPad Prism4 (GraphPad Software Inc.San Diego, CA). Statistical analysis 
(non parametric Mann Whitney test) was done in Prism 4. 
5.2.5 THP-1 Cell Culture 
The acute monocyte-like cells THP-1 were purchased from American Type Culture 
Collection (ATCC TIB 202, Rockville MD). The cells were maintained in complete media 
composed of RPMI-1640 containing 10 mM Hepes buffer, 1 mM sodium pyruvate, 1 mM L-
glutamine, 4.5 g/l D-glucose, 0.05 µM 2-mercaptoethanol and 10% fetal bovine serum. Cells 
were kept in tissue culture flasks in a humidified incubator at 370C, 5% CO2.  
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5.2.6 THP-1 Membrane Fragility Experiments 
  Cells were pelleted by centrifugation at 250 x g, 40C, for 10 minutes. The supernatant was 
discarded and the pellet was resuspended in 1.0 ml AS. Viability, as checked by trypan blue, 
ranged between 95 – 99 %. Cells were enumerated and split into two tubes.  In one tube labeled 
as Thal-THP-1, thalidomide was added at 4 µg/ml; whereas, in another tube, an equivalent 
volume of AS was added and the tube was labeled as A/S-THP-1. The tubes were placed on a 
rocker for 30 minutes at room temperature (RT). The cell suspensions were then centrifuged at 
250 x g for 10 minutes, 40C. Supernatants were discarded and the pellet of each tube was 
resuspended in 1.0 ml AS. Cells were added in each well of plates containing dilutions of salt as 
described in Table 1.  The plates were incubated at RT for 30 minutes. After centrifugation 230 x 
g for 15 minutes at RT, supernatants were harvested and stored at – 800C. 
5.2.7 Isolation of Neutrophils and Fragility Experiments 
The dextran sedimentation technique, as described in the Current Protocols in 
Immunology, was used (Wiley and Sons., 2003). Briefly, whole blood was mixed with an equal 
volume of 3% dextran solution. After 20 minutes of incubation at RT the upper layer was 
collected in a clean tube. The suspension was pelleted at 250 x g, 50C for 10 minutes. The pellet 
was resuspended in normal saline and mononuclear cells were removed by Ficoll-Hypaque 
gradient centrifugation. The RBC/neutrophil pellet was subjected to hypotonic lysis to remove 
the RBC. After the final wash the neutrophils were resuspended in PBS containing 10 mM D-
glucose solution. The cells were pre-treated for 30 minutes with either thalidomide at 4.0 µg/ml 
or acid saline control. Cells were then exposed to various salt solutions as mentioned in Table 1. 
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After 30 minutes of incubation at RT, plates were centrifuged at 250 x g at RT for 10 minutes; 
100 µl of supernatant was transferred from each well in a plate and frozen at –70 0C.  
5.2.8 LDH Assay 
Supernatants were thawed and dispensed at 50 µl/well in microtiter plates. The Cyto Tox 
96 ® non-radioactive cytotoxicity assay (Promega, WI, USA) was used to assess the LDH 
presence in the supernatants.  The substrate was reconstituted in assay buffer and 50 µl of this 
substrate mix was added into wells containing the supernatants. The plate was covered and 
incubated in the dark, at RT for 30 minutes. The reaction was stopped with 50 µl /well of stop 
solution and absorbance was determined at 490 nm. . The intensity of color produced is directly 
proportional to the concentration of LDH in the culture supernatants. The OD obtained was used 
to calculate the % LDH from the following formula: 
% LDH =.    OD of experimental wells.  x 100 
          OD at maximum lysis (i.e. 0% NaCl) 
 
5.3 Results 
5.3.1 Thalidomide Stabilized the Erythrocyte Membrane 
In blood that was washed and at most of the salt concentrations tested, a significant 
reduction in % lysis was observed in thalidomide treated cells compared to AS treated controls. 
In blood that was not washed, no significant difference was obtained between drug and AS 
treated blood (Figure 5.1).  
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Figure 5.1. Osmotic Fragility Experiment of Washed Versus Not Washed RBC. Not washed 
blood  (A) or washed blood (B) was incubated for 30 minutes with thalidomide or acid saline. 
Osmotic fragility experiment was done. The % hemolysis of RBC was plotted against the 
different hypotonic NaCl solution Values represent average +/-standard deviation of 5 
experiments containing 4 replicate wells per treatment. * p <0.05, **p <0.01 and ***p <0.001 
(Mann-Whitney U test). 
 
5.3.2 Effect of Thalidomide on LDH Release by Neutrophils 
At 0.05 % NaCl, the median % LDH of thalidomide treated cells was markedly lower 
than that of acid saline treated; however, it was not significant (p = 0.1359). At all salt 
concentrations, no significant difference in LDH release was obtained between drug and solvent 
treated PMN (Figure 5.2). 
5.3.3 Effect of Thalidomide on LDH Release by THP-1 cells 
Although the median % LDH from thalidomide-treated cells was slightly lower than that 
of acid saline treated cells, especially at 0.2 % salt concentration, no significant difference was 




Figure 5.2.Lactate Dehydrogenase (LDH) Release Assay of Thalidomide-Treated 
Neutrophils (PMN).  PMNs, isolated from 3 healthy subjects, were pre incubated with 






Figure 5.3. Lactate Dehydrogenase Release Assay of Thalidomide-Treated THP-1 Cells. 
THP-1 monocyte-like cells were incubated with thalidomide (hatched bar) or acid saline (open 
bar) and subjected to solutions with different salt concentration. Cytotoxicity was measured by 
quantifying the amount of LDH released. .  
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5.3.4 Influence of Ingested Thalidomide on Osmotic Fragility of RBC 
The ex vivo osmotic fragility experiments showed no significant difference between pre-
thalidomide and post-thalidomide.  The usual pattern with increased lysis at low salt 
concentration and gradual decrease in lysis as isotonic normal saline was approached in all 
experiments (Figure 5.4). 
 
Figure 5.4. Osmotic Fragility of RBC from Subjects Treated with Thalidomide In Vivo. 
Blood was drawn from 12 subjects before (A1) and after (A2) intake of thalidomide. The placebo 




The beneficial effect of thalidomide in the treatment of inflammatory conditions has been 
well established. But no definitive mechanism for this anti-inflammatory property has been 
obtained so far. A characteristic common to such conditions treated by thalidomide is an influx 
of PMNs at the site of inflammation, resulting in tissue damage (Mabalay, M.C. et al, 1964; 
Burns, R.A. et al, 1985).  
A straightforward hypothesis for thalidomide’s anti-inflammatory mechanism may be a 
perturbation of membranes on cells with immune potential. It has been shown that thalidomide 
did not alter mononuclear cell surface molecules like CD4, CD5, CD2, CD8, HLA-DR, HLA-A, 
B and C (Shannon, E.J. et al, 1994). Inhibition of functions of inflammatory cells like PMN 
phagocytosis and/or perturbation of membranes inhibiting the oxidative burst may also be 
another possibility. Thalidomide has failed to influence the oxidative burst of neutrophils as 
shown in chemiluminescence as well as in NBT reduction assays (Barnhill, R.L. et al, 1984; 
Golhman-Yahr, M. et al, 1978). This drug showed a bimodal activity with suppression of 
phagocytosis of latex beads by PMNs at a higher concentration and enhancement at a lower 
concentration (Barnhill, R.L. et al, 1984). But, it failed to affect the phagocytosis of larger 
particles like zymosan (Hastings, R.C. et al, 1978).  
The initial step in the oxidative burst event is the reduction of oxygen to O2- at the expense 
of NADPH. This reaction is catalyzed by neutrophil membrane-associated enzymes known as 
NADPH oxidase. Agents that perturb the integrity of the PMN and/or the lysosome membranes 
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have been demonstrated to significantly reduce the production of reactive oxygen species (Wiles, 
M.E et al, 1994; Hastings, R.C., 1971). Membrane stabilization of neutrophils as well as other 
eukaryotic cells as a possible mechanism of anti-inflammatory role exerted by thalidomide was 
investigated.  
Certain drugs like the macrolide antibiotics erythromycin and clarithromycin are shown to 
exert their anti-inflammatory action by stabilizing PMN membranes (Eriksson, T. et al, 1997). 
Thalidomide stabilized the RBC membrane as seen by the reduction in the percentage hemolysis 
of RBC exposed to low salt concentrations. This stabilization was confined to washed blood 
only. Thalidomide failed to affect the integrity of RBCs from blood that was not washed. This 
could be due to binding of thalidomide to proteins like human serum albumin and effectively 
depleting the concentration of thalidomide in the plasma (Eriksson, T. et al, Al., 1997). 
However, concentrations of thalidomide as high as 16 µg/ml in not washed RBC did not alter the 
integrity of the membranes (data not shown). Washing would remove these proteins increasing 
the interaction of the drug with RBC membranes. 
The ex vivo study of osmotic fragility on blood samples from human subjects before and 
after ingestion of 100 mg/ml thalidomide tablets, revealed no significant difference in the 
resilience of the RBC to the hypotonic solutions before and after intake of thalidomide. The 
concentrations of unhydrolysed thalidomide under this steady state condition are likely to be 
between 2 and 4 µg/ml (Eriksson, T. et al, 1997). Partial interaction of thalidomide with soluble 
proteins might have hindered the stabilization effect of thalidomide.  
 78
   Lactate dehydrogenase, a stable cytosolic enzyme released during cell lysis, was used to 
assess the effect of thalidomide on neutrophils and THP-1 cell membranes. There was no 
significant difference between thalidomide-treated neutrophils compared to AS treated-ones. The 
membrane stabilizing property of macrolide antibiotics is strongly associated with significant 
reduction in the oxidative burst by PMN (Theron, A.J. et al, 2000). The lack of stabilizing effect 
on PMN by thalidomide in this study is in concordance with previous findings where 
thalidomide failed to affect the production of reactive oxygen intermediates by neutrophils 
(Barnhill, R.L. et al, 1984; Golhman-Yahr, M. et al, 1978). 
   To assess the effect of thalidomide on monocyte/macrophage membranes the monocyte 
like cell THP-1 was used. Although thalidomide was previously reported to suppress the 
production of ROI by activated human monocyte in a chemiluminescence assay (Barnhill, R.L. 
et al, 1984), a difference between drug treated and solvent treated THP-1 cells was not seen.  
This confirms other studies that the anti-inflammatory mechanism of thalidomide is not 
explained by events associated with the modulation of superoxide anions.  
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CHAPTER 6 CONCLUSION 
 
The objectives of this work were to study the immunomodulatory, anti-inflammatory and 
anti-microbial properties of thalidomide in relation to leprosy. Elucidating the mechanism behind 
the dramatic effect of thalidomide in the treatment of ENL would facilitate an understanding of 
the cause(s) of ENL and the development of non-teratogenic analogues that can be used in the 
treatment of ENL. 
The influence of thalidomide on the immune response of leprosy patients’ cells, with ENL 
and RR or without reactions, to M. leprae-specific antigens was assessed. In the main phase of 
the study lymphocyte proliferation assays and the assessment of the synthesis of TNF-α were 
performed. The effect of thalidomide on these two parameters was controversial. Thalidomide 
has been previously reported to suppress TNF-α (Sampaio, E.P., et al 1991) or enhance TNF-α 
(Shannon, E.J. and Sandoval, F., 1996). In lymphocyte proliferation studies, thalidomide 
enhanced (Marriott, J.B. et al, 2002; Corral, L.G. et al, 1999 Haslett, P.A.J. et al, 1999), 
suppressed (Keenan, R.J. et al, 1991) or had no effect (Günzler, V. et al, 1986 Santos-Mendoza, 
T. et al, 1996; Shannon, E.J. and Sandoval, F., 1995). In some of these studies, the method of 
thalidomide preparation was not described or used procedures that indicate probable degradation 
of thalidomide. In other studies, concentrations as high as 50 µg/ml were used. In this study, 
thalidomide was prepared with an awareness of its susceptibility to hydrolysis and used in 
concentrations equivalent (i.e. 4.0 µg/ml) to that achieved in the plasma of patients treated for 
ENL. 
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In the first phase of the study, with the exception of a significant enhancement of 
proliferative responses to DHAR antigen in RR patients, thalidomide failed to modify the ability 
of cells to incorporate 3H-Thymidine. Thalidomide suppressed TNF-α in response to DHAR in 
healthy controls. Patients with ENL did not respond well in the assays to the AFB, DHAR or 
PPD antigen preparations. The majority of these patients were being treated with prednisone and 
their cells were probably in a hyporeactive or anergic state.  Interestingly, in 4 of 7 RR patients, 
thalidomide enhanced the production of TNF-α in response to AFB. Some of these RR patients 
were under steroid treatment.  This prompted further investigation of this observation among 
non-steroid-treated RR patients.  
In a second phase of the study, a significant enhancement in proliferation in response to 
DHAR and the cytosolic antigen MLSA was observed in non-treated RR patients. In the RR 
group as well as the non-reactional leprosy controls and the healthy controls, TNF-α was 
significantly suppressed due to thalidomide treatment. This confirmed a recently reported co-
stimulatory property of thalidomide (Marriott, J.B. et al, 2002), which might explain the absence 
of effect against RR. As in the first phase of the study, 11 of 68 RR patients responded to 
treatment with thalidomide and AFB, with enhanced lymphocyte proliferation, enhanced 
expression of TNF-α mRNA and enhanced the synthesis of TNF-α.   
 In a third phase of this work, the effect of thalidomide on the viability of M. leprae was 
assessed. Histopathologic studies of ENL have indicated the abundant presence of granulated M. 
leprae in lesions. The mechanism behind the release of M. leprae antigen from macrophage from 
certain lepromatous leprosy patients is not understood. Whether thalidomide interferes with the 
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viability of intracellular M. leprae and thereby may retard the release of M. leprae antigens was 
investigated. Mouse peritoneal macrophages non-activated or IFN-γ-LPS-activated and infected 
with M. leprae were treated with thalidomide in culture. This drug failed to affect the viability of 
intracellular M. leprae in a significant manner in the non-activated or activated macrophages. 
Thalidomide did not influence the production of neither TNF-α nor NO2- by these activated and 
infected macrophages.   
 Thalidomide had been shown to stabilize lysosomal membranes derived from rat liver 
homogenates. This property of thalidomide was proposed as its possible anti-inflammatory 
mechanism in the treatment of ENL (Hastings, R.C. 1971). In the last phase of this study the 
effect of thalidomide on the plasma membranes of neutrophils, THP-1 cells and red blood cells 
was studied. Thalidomide failed to protect the plasma membrane of neutrophils and THP-1 cells 
from osmotic lysis. In vitro, thalidomide stabilized RBC in blood depleted of plasma but it failed 
to do so in whole blood and in the blood of normal males ingesting thalidomide. Overall 
thalidomide did not alter the viability of M.  leprae, nor the integrity of the plasma membrane of 
inflammatory cells.  It could enhance or suppress M. leprae antigen-induced synthesis of TNF-α.  
Interestingly, in 15 of 75 RR patients cells stimulated with AFB, thalidomide acted as a co-
stimulant enhancing cell proliferation, synthesis of mRNA for TNF-α and TNF-α. 
Thalidomide’s enhancing effect on TNF-α in RR appears to be dependent on the stimulant and 
IL-2 signaling. As the inflammation in RR is associated with the emergence of antigen-reactive 
T-cells and TNF-α, we speculate that the use of thalidomide in the treatment of RR may 
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APPENDIX - RELEVANT EXTRA MATERIAL 
 
DEVELOPMENT AND VALIDATION OF A GEAOGRAPHIC INFORMATION RISK 




The multi-drug treatment approach of the WHO Global Leprosy Elimination Campaign 
has reduced the prevalence of leprosy in the world. According to WHO, since 1985, the global 
prevalence has been reduced by 90 % with a current prevalence/10,000 of 1.4 (Int. J. Lepr. Other 
Mycobact. Dis S21-S22, 2002). However, this reduction in prevalence does not appear to be 
successful in interrupting the transmission of leprosy. For the past 10-15 years, stable numbers of 
new cases have been recorded yearly, and in the 6 countries that account for approximately 90 % 
of new cases the incidence is even rising (Durheim, D.N. and Speare, R., 2003; Lockwood 
D.N.J., 2002). This increase in incidence is explained by some agencies to be due to increased 
detection of hidden cases through improved case detection services and special education 
campaigns. Although this might be true for the incidence among patients with advanced disease 
or disability, it does not explain why children make up 13 % of the new cases (Lockwood, D.N.J. 
2002). 
The relationship among Mycobacterium leprae, the human host and the chain of 
infection, which may lead to development of leprosy, are not clear. Leprosy is believed to be 
transmitted by inhalation of nasal droplets containing M. leprae. Lepromatous leprosy (LL) 
patients, who harbor viable bacilli in nasal secretions, are thought to be the main source of 
infection (Hastings, R.C., 1993). Yet little correlation exists between prevalence of LL and the 
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total new cases registered. The incidences of conjugal leprosy and of individuals with frequent 
contact with cases are also insignificant (Jopling, W.H., 1988).   
The rate of infection by M. leprae is much greater than the rate of disease development 
indicating the presence of sources of infection other than the leprosy patients (Fine, P.E. et al, 
1997). Alternative sources of M. leprae infection could be a sub-clinically infected individual, an 
animal or insect vector or a contamination in the environment.  
According to the WHO, Ethiopia in 1999 reached the leprosy elimination target of 1case 
/10,000 populations; however, as with other countries, the incidence has not changed appreciably 
with about 5,000 new cases detected yearly. In 2002, clusters of endemicity with prevalence 
rates higher than the elimination target was recorded in 4 of the 14 administrative divisions 
namely the Oromia, Amhara, the Southern Nations and Nationalities (SNNP) and Tigray  
(Tuberculosis and Leprosy Control of Ethiopia10th Annual Review Meeting, 2002).  
Environmental sources have long been suspected to play a role in the spread of leprosy 
especially due to the geographical differences in leprosy distribution and local clustering. 
Previous beliefs that M. leprae cannot survive once outside the human body are now changing. 
Under favorable conditions such as hot humid climate, M. leprae is capable of surviving for 
months (Dessikan, K.V. and Sreevatsa, 1995).  
An objective of this work was to use geographic information systems (GIS) to assess the 
influence of environmental factors on the prevalence of leprosy in Ethiopia. The application of 
GIS in epidemiology has facilitated our understanding of spatial variations of diseases and their 
relationship to the environment. The environmental attributes selected for analysis were 
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normalized difference in vegetation index (NDVI), earth surface temperature (TMax), and a 
climate data including point potential evapo-transpiration (PPE), average maximum and 
minimum temperatures. These attributes were analyzed for their suitability for leprosy 
prevalence in the Oromia region in Ethiopia. Arc View GIS 3.3 and Genetic Algorithm for Rule-
set Prediction (GARP) were used to build models and to create maps showing the distribution of 
leprosy in the region. The independent leprosy data set from the Amhara region was then used to 
validate the leprosy prediction model.  
Material and Methods 
 
Baseline Data. The data was prepared by the Amhara and Oromia Regional Bureaus of Health 
and the Ethiopian Ministry of Health. Cases include both the severe forms of multibacillary 
leprosy (MB) as well as the milder form known as paucibacillary leprosy (PB). As of June 2001, 
the total number of PB (N=1367) and PB (318) cases recorded in 285 zonal health institutions in 
the Amhara region was used in this study. The total PB (N=136) and MB (N=2402) cases for the 
Oromia region collected as of August 2003, comprised data from 124 health institutions.   
Determination of geographical coordinates. The latitude and longitude of each clinic was 
obtained in geographic decimal degree format from the website of the National Imagery and 
Mapping Agency NIMA)(http://gnps.www. nima). Coordinates not found were obtained from 
Encarta (Microsoft Encarta, 2002). Digital mapping of the point coordinates for each clinic was 
prepared in Arc View GIS 3.3. 
The Minimum Medical Database (MMDb). This database was prepared by collaborating health 
workers and earth scientists interested in the application of geospatial sciences to control 
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program management and research for schistosomiasis and other snail-borne diseases. The 
database contains information for the Intergovernmental Authority of Development/Nile Basin 
(IGAD/Nile) region of East Africa, which includes Ethiopia. The MMDb available in CDROM 
(http://www.gnosis.org) contains useful maps and compiled data on environmental attributes 
such as normalized difference in vegetation index (NDVI), earth surface maximum temperature 
(TMax), elevation, soil types; infrastructures like roads, rail roads, utility lines; political 
boundaries and population data for the region of East Africa (Malone, J.B. et al, 2001). All 
parameters tested in this study were taken from the MMDb . 
Table.1. Data Used for Analysis 
Parameter Feature Type Source 
NDVI 8-bit Image United States Geological Survey (USGS) 
TMax 16-bit Image USGS 
ACT Climate Grid Blackland Research and Extension Center, Texas 
Agricultural experiment station 
NDVI, TMax for 
GARP 
Image Clipped and modified with GARP Dataset Manager 
 
Prevalence Calculation and Normalization of Data. To avoid confounding factors like clinic size 
and number of people living around each clinic and to obtain comparable data, we calculated the 
prevalence of leprosy per 10,000 populations for both the Amhara and Oromia regions. 
Oromia Region: the data for this region contains number of inhabitants in each zone. We 
used these data to calculate the prevalence of leprosy/10,000 for each clinic. 
Amhara Region: the total population per each zone was estimated by creating a 10-km 
diameter buffer zone surrounding each leprosy clinic and extracting the density; the total 
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population was calculated from the population density and used for the determination of 
prevalence/10,000 for each clinic.  
Extraction of Environmental Data. All extractions of environmental feature data, including 
Advanced Very High Resolution Radiometer (AVHRR) satellite sensor data, were based on the 
10-km diameter buffer zone around each clinic. We used the Oromia data for creation of models 
and the Amhara data for validation of created models. 
Normalized Difference in Vegetation Index NDVI (1992-1995) 
AVHRR data for daytime land surface temperature (TMax) and Normalized Difference 
Vegetation Index (NDVI) for 1992-1993 and 1995-1996 was obtained from the United States 
Geological Survey (USGS) global 1km2 website (Huh, O.K. et al, 2001). NDVI is an index that 
ranges from 0 to 200 with increasing green vegetation. It is an indicator of soil moisture based on 
vegetation. The AVHRR data, which consists of decadal (10-day) composites of daytime 
imagery, was processed by the USGS to minimize cloud cover and atmospheric attenuation of 
sensor signal. All downloaded images were calibrated and geo-referenced to a geographic 
decimal degree latitude and longitude coordinate system using ERDAS imagine 8.6 image 
processing software. The decadal images were averaged to create monthly composites, which 
were averaged together to create maps for dry (October-March) and wet (April-September) 
seasons and an annual composite map, which included both seasons.   
The NDVI image files were converted into a grid file and used for extraction of mean 
NDVI value for each buffer zone. The extracted data were exported as Dbase files into Microsoft 
excel datasheets. Scatter diagrams of Cases/10,000 versus mean NDVI were plotted in Microsoft 
 99
Excel. Outliers such as buffer zones falling fully or partially in water were excluded. A range of 
NDVI that comprises all prevalence data points was determined from the plot and used to 
perform queries in Arc View 3.3 GIS to create map overlays showing areas suitable for leprosy 
prevalence.   
TMax, (1992-1995) 
TMax is the earth surface maximum temperature from AVHRR channel 4, which is used 
as an indicator of temperature (Huh, O.K. et al, 2001). Similar to the NDVI data, the image files 
for TMax were prepared for the dry, wet and annual seasons. The same extraction procedures 
were applied to obtain a range of TMax suitable for the prevalence of leprosy in the regions. 
Scatter plots were prepared in Microsoft excel and the range was then used as the criteria for 
queries in Arc view 3.3 GIS to create map overlays. The Amhara prevalence data points were 
overlaid on the model and points falling inside and outside the model were determined for 
calculation of positive and negative predictive values. 
Almanac Characterization Tool (ACT) Climate Data. This is a climate grid file (5 x 5 km2 cell 
size), which contains 30 years average data for precipitation (pre), potential evapo-transpiration 
(pet), point potential evapo-transpiration (ppe= pre/pet) and the minimum (It) and maximum 
temperature (xt) for January up to December. Ppe is an indicator of water budget of the soil. The 
leprosy prevalence point table was joined to the climate data table based on the grid cell. The 
linked tables was exported as a DBase file and mean temperature ([It +xt]/2) and mean ppe were 
calculated for dry season (October to March) and wet season (April to September) to give dry T, 
wet T, dry PPE and wet PPE values. Scatter plots of these values versus the stratified 
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prevalence/10,000 (0-0.1, 0.1-0.7 and > 0.7) were used to define ranges that included 95% of all 
points (Table 2) for creation of map overlays in Arc view 3.3 GIS.  
Ecologic Niche Modeling GARP. The annual composites data for TMax and NDVI were used as 
environmental dimensions for the ecologic niche modeling. Environmental layers for the analysis 
were prepared by converting the image files to grid and processing of these files using the GARP 
module in Arc View GIS 3.3. These files were transformed to GARP compatible format with the 
GARP Dataset Manager.  The Amhara and Oromia leprosy prevalence data were combined to 
generate a total of 317 occurrence points. These distributional points were loaded into Desktop 
GARP and used to model ecologic niches and potential geographic distribution of M. leprae. 
GARP equally divides the loaded prevalence data into training and test data sets. Multiple 
iterations based on rule selection, evaluation, testing and incorporation or rejection is performed. 
The training data sets are subjected to randomly selected statistical methods like logistic 
regression, bioclimatic rules to develop a procedure to be used to evaluate the predictive 
accuracy based on test data sets and points randomly sampled from the whole region as a whole 
(Towsend, A.P. et al, 2001). For each set of data used GARP generates 20 models. Three criteria 
were used for the selection of the best model; (1) elimination of models with high number of 
training points omitted and when possible including only those models with 0 omission; (2) the 
average of total area predicted for species to be present was calculated and models falling within 
5% range below or above this average were selected and (3) models that passed the two criteria 
were compared based on the p value for Chi-square analysis of the probability of a random 





Point locations of the 123 health institutions in the Oromia region and the 285 health institutions 
in the Amhara region were mapped in Arc View 3.3. 
Scatter plots of Oromia prevalence data versus NDVI or TMax, prepared in Microsoft Excel, 
were determined to define ranges that included 95 % of all leprosy prevalence points. The NDVI 
value ranges were 116-154.5 for the annual composite, 116-161 for the dry season map and 115-
155 for the wet season map. TMax ranges were 9.4-28.80C for the annual composite, 11.7-
32.50C for the dry season map, 7.7-25.80C for the wet season map.  These ranges were used to 
prepare query-based map overlays showing all areas that met both the NDVI and TMax criteria 
ranges in the country. We selected the annual composite model that covers all seasons 
throughout the year. This model showed except for areas in the South East (Somali) and North 
East (Afar), that most places in the country were found to be suitable for leprosy (Figure 1). The 
positive predictive value calculated using the Amhara data was 90.5 %. All of the prevalence 
points that fell outside the predicted area were in the lowest ranges of prevalence/10,000 (0 – 
0.1). 
The ACT climate grid was used to determine the influence of thermal-hydrologic regime (PPE 
and PET) in relation to leprosy distribution. Table.2 shows the defined ranges of potential evapo-
transpiration and minimum and maximum temperatures for the dry and wet seasons The climate 
model predicted most of the Amhara and the Oromia region except the southern part, most of the 
Southern Nation and Nationality (SNNP), Harari and DireDawa (Figure 2.). The model excluded 
Somali, most parts of Afar especially the Eastern part, Northern Tigray and Western Gambela. 
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The positive predictive value generated using the Amhara data was 87.8%. Except for Chagnie 
(prevalence/10,000 = 1.32), all the prevalence points not predicted by the model had a 








Table 2. Temperature and PPE Ranges Used in ACT Climate Query 
Prevalence 
Class 
Dry season T in 
0C 




Wet season PPE 
0 - 0.1 11.6 - 17.9 11.6 - 21.0 0.12 - 0.42 1.03 - 2.61 
0.1 - 0.7 9.8 - 24.3 9.6 - 25.3 0.12 - 0.6 0.59 - 2.9 







 The GARP M. leprae distribution model is the most powerful of all models due to 
restrictions and statistical methods employed for its generation. This model is inclusive of all of 
the Amhara and Oromia points while the other two models were based on the Oromia data only.   
The prediction pattern of this ecologic niche model resembles the annual composite prediction 
model. It included most of the Amhara, Oromia, SNNP, Tigray and Gambela regions and 





Understanding of the natural history of a disease, its ecologic distribution and the 
essential host-pathogen interactions are necessary in order to establish a successful control 
program. The WHO leprosy elimination campaign, mainly based on case finding, treatment and 
follow-up of household contacts, has not reduced the incidence of leprosy. Enhanced detection of 
hidden cases cannot explain the new occurrence of leprosy among young children, an indicator 
of ongoing active transmission (Int. J. Lepr. Other Mycobact. Dis S21-S22, 2002). 
 Several countries that reached the elimination target have localities with clusters of 
leprosy. These high endemicity regions must be eliminated in order to achieve sustained low 
transmissions and reduced incidence rates. Ethiopia is one example where leprosy elimination is 
achieved but there are districts with leprosy prevalence above the 1 case/10,000 cut-off defined 
by WHO to be an endemic area. The transmission rate in children below 15 years of age is about 
6%. Out of the total leprosy cases recorded in Ethiopia in 2002, 46% occurred in Oromia, the 
largest administrative region in the country, followed by the Amhara region with 31.5 % of the 
total new cases (Tuberculosis and Leprosy Control of Ethiopia10th Annual Review Meeting, 
2002).   
GIS techniques were used in the current study to develop leprosy prediction models for 
Ethiopia. Thermal-hydrologic regime, as defined by AVHRR satellite sensor data on moisture or 
humidity, land surface temperature plus conventional climate data were included as potential 
environmental factors that might determine the distribution and abundance of the disease. 
Annual composite image files for NDVI, an indicator of moisture regime and vegetation vigor, 
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and TMax an indicator of temperature regime (Huh, O.K. and Malone, J.B., 2001) were used to 
create the AVHRR satellite sensor based model. This TMax/NDVI combined model showed a 
major part of the country was suitable for occurrence of leprosy. A second model based on 
climate station data on precipitation (PRE), Potential evapo-transpiration (PET), the PRE/PET 
ratio also known as point potential evapo-transpiration (PPE) and maximal and minimal 
temperatures for each month was also created. PPE indicates the moisture content of soil (water 
balance) was included to validate the previously reported association of M. leprae with moisture 
(10). The climate-based model with stratified prevalences (0-0.07, 0.07 – 0.1 and 0.1 to 71.3 
cases/10,000 population) predicted the highest risk in Amhara and Oromia, the two regions with 
highest leprosy incidence (Tuberculosis and Leprosy Control of Ethiopia10th Annual Review 
Meeting, 2002).  
The ecologic niche of a species is the suitable ecologic space within which a species is 
potentially able to maintain population without immigration. GARP is a high precision computer 
based genetic algorithm system used in ecologic niche modeling. It has a high predictive ability 
of species potential distributions based on user selected environmental layers. GARP 
incorporates different procedures that involve powerful rules including atomic rules, logistic 
regression analysis and the frequency distribution-based bioclimatic rules. The GARP model has 
minimum errors of omissions and commissions making it an important tool in understanding the 
geographical distribution of the species of interest (Townsend, A.P. et al, 2001; Costa, J. et al, 
2002). 
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The third model GARP, based on input variable of NDVI and TMax annual composite 
value confirmed what we saw in the annual TMax/NDVI model. It predicted most of Amhara 
and Oromia regions as the two major leprosy areas in Ethiopia.  
All three models excluded the dry and hot Afar and Somali area, the 2 regions with the 
least number of leprosy cases in Ethiopia in 2002 (Tuberculosis and Leprosy Control of 
Ethiopia10th Annual Review Meeting, 2002). 
M. leprae is capable of withstanding severe adverse environmental conditions while to 
remain viable. Hot and humid weather, wet soils, water and low temperatures, are all 
demonstrated to favor survival of the bacilli for a few months (Desikan, K.V. and Sreevatsa, 
1995; Desikan, K.V., 1977). M. leprae DNA has been detected in water in Indonesia at locations 
where a high proportion of individuals utilizing this water were affected by leprosy (Matsuoka, 
M. et al, 1999). A well-controlled study in Karonga district in Malawi has shown water and soil 
moisture to be associated with high prevalence of leprosy (Sterne, J.A.C. et al, 1995). Indirect 
transmission of leprosy is further supported by the natural occurrence of leprosy in animals like 
armadillos (Job, C.K. et al, 1986) and reports on the potential of insects to transmit leprosy  
(Geater, J.G., 1975; Banerjee, R. et al, 1990).  
Our study indicates that leprosy may be associated with specific environmental features. 
The models we developed seem to be in concordance with leprosy distribution in Ethiopia and 
support the conclusion that: (1) certain thermal-hydrological regimes favor survival of leprosy in 
the environment and that (2) both NDVI and TMax may be incorporated in the predictive model 
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of leprosy. This can be measured by conventional climate station data or by satellite-sensor data 
on NDVI and TMax as surrogates of moisture and temperature respectively. 
Various parameters have been identified as risk factors in acquiring leprosy disease. 
These include demographics like age and sex and immunological factors like the absence of 
BCG vaccination (Ponnighaus, J.M. et al, 1993). A significant negative correlation between the 
incidence of leprosy and higher economic indices has been reported (Di, Z. et al, 1993). Rural 
endemic settings with poor housing and sanitation conditions have been described as important 
factors in the transmission of leprosy (Mani, M.Z., 1996). For any of these factors to have a role 
in the development of leprosy, the sustained presence of M. leprae in the environment is 
necessary. We propose that leprosy occurs most frequently when a suitable microenvironment 
like moist soil coexists with other known or unknown predisposing factors.  This study provides 
evidence that environmental factors are of importance in the prevalence of leprosy. Such factors 
must be taken into consideration when planning a control program. Further studies that 
incorporate field-collected validation data (ground truth) may shed more light into the precise 
thermal-hydrological regime factors or other risk factors associated with the environmental risk 






Banerjee, R., Chaudhury, S. and Hati, A.K. 1990. Transmission of Mycobacterium leprae from 
lepromatous leprosy patients to the skin of mice through intermittent feeding.Trop. Geog. 
Med. 42(1): 97-99. 
 
Costa, J., Towsend, A.P., Beard, C.B. 2002. Ecologic niche modeling and differentiation of 
populations of triatoma brasiliensis neiva, 1911, the most important Chagas’ disease vector in 
Northeastern Brazil. Am. J. Trop. Med. Hyg. 67(5): 516-520. 
 
Desikan, K.V., Sreevatsa. 1995. Extended studies on the viability of M. leprae outside the human 
body. Lep. Rev. 66: 287-295. 
 
Desikan, K.V.1977. Viability of Mycobacterium leprae outside the human body. Lep. Rev. 48: 
231-235. 
 
Di, Z., Yuewen, N. and Jingzeng, Z. 1992. Leprosy-economy-environment; might we predict 
leprosy incidence from this point of view? Int. J. Lep 61(4): 631-632. 
 
Durrheim, D.N., Speare, R. 2003. Global leprosy elimination: time to change more than the 
elimination target. J. Epidemiol. Comm. Health 57: 316-317. 
 
Fine, P.E., Sterne, J.A., Ponnighaus, J.M., Bliss, L., Saui, J., Chihana, A., Munthali, M., 
Warndorff, D.K. 1997. Household and dwelling contact as risk factors for leprosy in Northern 
Malawi. A. J. Epidemiol. 146(1): 91-102. 
 
Geater, J.G. 1975. The fly as potential vector in the transmission of leprosy. Lep. Rev. 46: 279-
286. 
 
Hastings RC. 1993. Leprosy. 2nd edition, RC Hastings, Ed; pp 137-155. Churchill Livingston, 
Edinburgh, UK. 
 
Huh, O.K. and Malone, J.B. 2001. New tools: potential medical applications of data from new 
and old environmental satellites. Acta Tropica 79(1): 35-47.  
 
Job, C.K., Harris, E.B., Allen, J.L. and Hastings, R.C. 1986. A random survey of leprosy in wild 
nine-banded armadillos in Louisiana. Int. J. Lep. 54(3): 453-457. 
 
Jopling, W.H. 1988. Handbook of leprosy. 4th edition. Heinemann Professional Publishing 
 110
 
Lockwood, D.N.J. 2002. Leprosy elimination- a virtual phenomenon or a reality. B.M.J. 324: 
1516-1518. 
 
Malone, J.B., McCarroll, J.C., Kristensen, T.K., Yilma, J.M., Erko, B., El-Bahy, M.M. and 
Corbett. 2001. Minimum Medical Database spatial decision support system for the Authority 
on development-Nile Basin Region (IGAD-Nile).  
 
Mani MZ. 1996. Ecologic factors in transmission of leprosy. Ind. J. Lep. 68(4): 375-376. 
 
Matsuoka, M., Izumi, S., Budiawan, T., Natak, N. and Saeki, K. 1999. M. leprae DNA in daily 
using water as a possible source of leprosy infection. Indian J. Lep. 71(1): 61-67. 
 
Ponnighaus, J.M., Fine, P.E., Sterne, J.A., Bliss, L., Wilson, J.R., Malema, S.S. and Kileta, S. 
1993. Incidence rates of leprosy in Karonga district, Northern Malawi: patterns by age, sex, 
BCG status and classification. Int. J. Lep. 62(1): 10-23. 
 
Sterne, J.A.C., Ponnighaus, J.M., Fine, P.E.M. and Malema, S.S. 1995. Geographic determinants 
of leprosy in Karonga district, Northern Malawi. Int. J. Epidemiol. 24(6): 1211-1222. 
 
The Global situation of leprosy control at the beginning of the 21st century. 2002. Int.J.Lep. 
70(1S): S21-S22. 
 
Towsend, A.P. and Vieglais, A.D. 2001. Predicting species invasions using ecological niche 
modeling: new approaches from bioinformatics attack a pressing problem. Bioscience 51(5): 
363-371. 
 
Tuberculosis and Leprosy control of Ethiopia. 2002. Tenth Annual Review Meeting.18 to 20 
September, 2002. 
 




Azeb Tadesse Argaw was born in Addis Ababa, Ethiopia, to Tadesse Argaw Negash and 
Asrat Negash H/Wolde. She attended the French school Lycee Guebre Mariam in Addis Ababa. 
In December 1991, she completed her Bachelor of Science degree in pharmacy from the Addis 
Ababa University. She worked as a research assistant at the Armauer Hansen Research Institute 
in Addis Ababa. In August 1995, she went to Bergen, Norway, to pursue her master at the Center 
for International Health. In June 1998, she obtained her Master of Philosophy in immunology. 
She returned back to AHRI and worked as a senior research assistant. In May 2001, she joined 
Louisiana State University as a doctoral student.   
She is planning to pursue a postdoctoral work in molecular immunology of multiple sclerosis 
at Mount Sinai School of Medicine in New York. 
 
 
